

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Haemodynamic effects of a 10-minute treatment with a high inspired oxygen concentration in the Emergency Department: a prospective observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059848
Article Type:	Original research
Date Submitted by the Author:	23-Dec-2021
Complete List of Authors:	Stolmeijer, Renate; University Medical Centre Groningen, Department of Emergency Medicine VAN IEPEREN, Ellen; Medical Centre Leeuwarden, Department of Emergency Medicine LAMEIJER, Heleen; Medical Centre Leeuwarden, Department of Emergency Medicine VAN BEEST, Paul; Medical Centre Leeuwarden, Department of Anaesthesiology ter Maaten, Jan; University Medical Centre Groningen, Emergency Department, Department of internal medicine ter Avest, Ewoud; University Medical Centre Groningen
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Adult intensive & critical care < ANAESTHETICS, INTENSIVE & CRITICAL CARE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Haemodynamic effects of a 10-minute treatment with a high inspired oxygen concentration in the**
4
5 **Emergency Department: a prospective observational study.**
6
7
8
9

10 Renate STOLMEIJER¹, Ellen VAN IEPEREN², Heleen LAMEIJER², Paul VAN BEEST³, Jan C. TER
11
12 MAATEN⁴, Ewoud TER AVEST^{1,5}.
13
14
15

16 ¹ Department of Emergency Medicine, University Medical Centre Groningen, the Netherlands.
17

18 ² Department of Emergency Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
19

20 ³ Department of Anaesthesiology, Medical Centre Leeuwarden, the Netherlands.
21
22

23 ⁴ Department of Internal Medicine, University Medical Centre Groningen, the Netherlands.
24

25 ⁵ HEMS, Kent, Surrey and Sussex Air Ambulance Trust, Redhill, Surrey, United Kingdom.
26
27
28
29

30 **Correspondence to:**

31
32 Renate Stolmeijer, MD: t.m.stolmeijer@umcg.nl
33
34
35
36

37 **Short title:** The effects of short term hyperoxia on cardiac output in the ED.
38
39
40

41 **Word count:** 3313
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Previous studies have shown that prolonged exposure to a high inspired oxygen concentration (FiO_2) is associated with unfavourable hemodynamic effects. Until now, it is unknown if similar effects also occur after oxygen therapy of limited duration in the emergency department (ED).

Objectives. To investigate the hemodynamic effects of a high FiO_2 administered for a limited duration of time in patients who are preoxygenated for PSA in the ED.

Design, settings and participants. In a prospective cohort study, cardiac output (CO), stroke volume (SV) and systemic vascular resistance (SVR) were measured using the ClearSight® non-invasive CO monitoring system in patients who were pre-oxygenated for PSA in the ED. Measurements were performed at baseline, after 5 minutes of preoxygenation via a non-rebreathing mask at 15L/min and after 5-minutes of flush rate oxygen administration.

Outcomes measures. The primary outcome was defined as the change in CO (L/min) from baseline after subsequent preoxygenation with 15L/min and flush rate.

Results. Sixty patients were included. Mean CO at baseline was 6.5 (6.0-6.9)L/min and decreased to 6.3 (5.8-6.8) L/min after 5 minutes of oxygen administration at a rate of 15L/min, and to 6.2 (5.7-6.70) L/min after another 5 minutes at flush rate ($p=0.037$). Mean SV remained relatively constant during this period, whereas mean SVR increased markedly (from 781 [649-1067], to 1244 [936-1695] to 1337 [988-1738] dyn/sec/cm⁵, $p<0.001$). Sixteen (27%) patients experienced a >10% decrease in CO.

Conclusion. Exposure of patients to a high FiO_2 for 5-10 minutes results in a significant drop in CO in 1 out of 4 patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited amount of time, FiO_2 should be titrated based on deficit and high flow oxygen should not be given as a routine treatment.

Key words: hyperoxia, inspired oxygen concentration, hyperoxemia, emergency department, oxygen therapy, procedural sedation and analgesia.

Strengths and limitations of this study:

- This is the first prospective study to investigate the hemodynamic effects of treatment of patients in the ED with a high FiO_2 for a limited duration of time (10 minutes).
- Non-invasive monitoring of cardiac output, stroke volume and systemic vascular resistance was used before- and during pre-oxygenation to quantify hemodynamic effects.
- Findings are highly relevant to both prehospital- and ED care providers, who often treat patients for a relatively limited duration of time with high-flow oxygen.
- Generalizability of the findings is limited due to relative homogeneity of the subjects included in the study. No patients with known heart failure were included.

Background

Oxygen is frequently administered in the Emergency Department (ED) and in the prehospital setting by emergency medical services (EMS). It is used both to treat- or prevent hypoxaemia in acutely ill patients and to pre-oxygenate (de-nitrogenate) patients for procedures such as rapid sequence induction (RSI) or procedural sedation and analgesia (PSA), (1-3). Often, oxygen is administered at a flow of 15 L/min or even higher (4) via a non-rebreathing mask (NRBM) in order to increase the end-expiratory oxygen fraction, and to de-nitrogenate the lungs, thereby increasing the save apnea time for PSA or RSI (5).

Oxygen administration, however, may not be without risk: Previous studies have shown that prolonged exposure to a high inspired oxygen concentration (FiO_2) is associated with higher mortality rate in patients hospitalised with various conditions (6-10). This may be explained by a negative effect on cardiac output mediated by peripheral- and coronary vasoconstriction resulting from direct effects of oxygen on smooth muscle tone (11,12), and by the formation of reactive oxygen species that contribute to (vascular) oxidative stress (13-16).

1
2
3
4
5
6 As opposed to hospitalised patients, patients in the prehospital setting and in the ED normally receive
7 high-flow oxygen only for a limited amount of time. Previous studies have nonetheless shown that
8 this results in significant hyperoxemia in many patients (17). The clinical relevance of this however, is
9 largely unknown, as until now, the hemodynamic effects of exposure of patients in the ED to a high
10 FiO_2 for only a limited duration of time have never been reported.
11
12
13
14
15
16
17
18
19
20

21 Therefore, in the present study, we aim to investigate the hemodynamic effects of a high FiO_2
22 administered for only a limited duration of time in patients who are preoxygenated for PSA in the ED.
23
24
25
26
27

28 **Methods**

29 Study Setting and Design

30 A single centre prospective study was performed in a cohort of patients undergoing pre-oxygenation
31 for PSA in the ED of the Medical Centre Leeuwarden, a teaching hospital in the Netherlands with an
32 27.000 ED visits yearly) between May 2018 to June 2019 (ClinicalTrials.gov (NCT03930979). Ethical
33 approval was sought and obtained from the ethical committee of the RTPO Leeuwarden (protocol
34 number nWMO 270).
35
36
37
38
39
40
41
42
43
44
45

46 Patient and public involvement

47 No patients were involved.
48
49
50
51

52 Study population

53 Patients were eligible for inclusion in the study if they were older than 18 years and were due to
54 receive PSA to facilitate a procedure in ED. Patients were excluded if PSA was needed immediately
55 according to the treating physician (no time to obtain informed consent and/or to perform necessary
56
57
58
59
60

1
2
3 calibration of the system used to measure CO), if they were pregnant, if they presented with
4 significant hypoxia (defined as an oxygen saturation <90% or a pO₂< 8.0 kPa), if they received oxygen
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

calibration of the system used to measure CO), if they were pregnant, if they presented with significant hypoxia (defined as an oxygen saturation <90% or a pO₂< 8.0 kPa), if they received oxygen supplementation pre-inclusion, if they had chronic obstructive pulmonary disease (COPD) GOLD I or II with hypercapnia (pCO₂ >6.4 kPa) or COPD GOLD III or IV, if they used bleomycine, if they presented with a cardiogenic shock (SBP<90 mmHg) or if they needed PSA for electrocardioversion- or pacing (for reasons of difficulty obtaining a reliable signal to measure CO). Patients could only be included once.

Study protocol

After informed consent was obtained from eligible patients, demographics, medical history and medication use, ECG at presentation and vital signs were obtained. Subsequently, the ClearSight® non-invasive cardiac output measurement system was attached to the patient and calibrated for continuous monitoring of blood pressure, CO, SV and SVR. Baseline values for these parameters were established as an average of three repeated measurements. Thereafter, oxygen was administered via a NRBM at a rate of 15L/min from a powered wall source, and measurements (CO, CI, SV, and SVR) were repeated after 5 minutes. No other interventions than oxygen administration were performed during this period, and no medication was administered. Thereafter, the rate of oxygen administration was increased to flush rate (30L/min), and after 5 minutes measurements were repeated. Thereafter, care as usual was provided for the conduct of PSA. (figure 1)

Data collection

The following parameters were collected on a dedicated Case Report Form (CRF) for all included patients: patient demographics including (cardiac) medical history and alcohol- nicotine- and medication use, ECG abnormalities at presentation, ASA classification and indication for PSA, and vital parameters (heart rate (HR), non-invasively measured systolic blood pressure (SBP), oxygen saturation (SpO₂), CO, SV and SVR).

Non-invasive cardiac output measurements

CO was measured non-invasively using The ClearSight® system (Edwards Lifesciences). The methodology of the ClearSight® is based on Nexfin technology of pulsatile unloading of the finger arterial walls using an inflatable finger cuff with a built-in photoelectric plethysmograph that uses pressure to maintain a constant blood volume in the finger. ClearSight® calculates beat-to-beat SV by dividing the area under the SBP curve (measured at 200 Hz) by the aortic input impedance (Z_{in}). The value of Z_{in} is determined from a three-element Windkessel model in which the nonlinear effect of MAP and the influence of the patient's age, height, weight, and gender on aortic mechanical properties are incorporated. Because the waveform at the finger shows a more undulatory appearance than the radial pressure wave- form, the system transforms the finger waveform into a brachial waveform with a specific filter. ClearSight® uses the integrated area under the pulsatile systolic waveform from the brachial pressure wave as an input to the model, which directly yields SV and produces CO by multiplying beat-to-beat SV by instantaneous heart rate. The Nexfin technology used in the ClearSight® is validated in multiple studies (18,19). All investigators received a training given by a trainer of the manufacturer of ClearSight® in how to operate the device before they were able to include patients for this study.

Outcomes

The primary outcome was defined as the absolute change in CO from baseline after respectively 5 minutes 15L O₂/min and 5 minutes flush rate oxygenation via a NRBM.

Secondary outcomes were defined as:

- The absolute change in HR, SBP, SV and SVR from baseline after respectively 15L O₂/min and flush rate oxygenation via NRBM.
- The number of subjects demonstrating a >10% change in CO* in response to oxygen administration (both 15L/min and Flush rate).

1
2
3
4
5 * a 10% change in CO was deemed clinically relevant as this corresponds to the effect of a Vasalva
6 manoeuvre (20) and has been shown to be a detectable change using a (non-invasive) method based
7
8 on pulse contour analysis (21).
9
10
11
12
13
14
15

16 Sample size

17
18 Based on previous literature (22) it was estimated that with a mean (SD) CO of 6.0 (0.8) L/min, 54
19 patients would be needed to allow the detection of a 10% decrease in CO as a result of procedural
20 sedation with a power of 90% and a type I error rate of 5%. To allow for an attrition rate of 10 % we
21 aimed to include 60 patients.
22
23
24
25
26
27
28
29
30

31 Statistical analysis

32
33 Continues variables are represented as mean (95% CI) or median (IQR) where appropriate. Repeated
34 measures ANOVA with Greenhouse Geiser correction and post-hoc testing (Tukey Kramer) was used
35 to analyze the difference in hemodynamic measurements at baseline and after preoxygenation with
36 NRBM 15L/min and flush rate oxygen. Comparisons between patients demonstrating a > 10% decrease
37 in CO and those who did not were made using Student's t-test, Mann-Whitney U test, or Fisher's exact
38 test where appropriate. Mixed ANOVA was used to calculate oxygen dose-to-group interactions for
39 these groups. Missing data were reported in the results section according to the STROBE guideline. A
40 *p*-value <0.05 was considered statistically significant. All statistical analysis were done with SPSS 23.0
41 for Apple statistical package (SPSS Inc, Chicago, Illinois, USA) and Vassarstats statistical software (Vassar
42 college, Poughkeepsie, New York, USA).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

59 **Results**

60

Characteristics of study population

During the study period, a total of 91 patients were screened for eligibility. Thirty-one patients were excluded after screening for various reasons (figure 2). Fourteen patients were excluded as no reliable signal for cardiac output monitoring could be obtained with the Clearsight® system. In 6/14 patients this was due to identifiable patient factors (cold hands, tremor), whereas in the remaining 8 patients the system software failed.

Baseline characteristics of the study population are shown in table 1. Median (range) age of the included subjects was 62 (18-92) years, with an equal gender distribution. A total of 16 patients (26,7%) used one or more cardiovascular drugs on a daily basis. There were no patients with pre-existent heart failure or a pacemaker in situ. Other patient characteristics, pre-hospital treatments, and vital signs at presentation are represented in table 1.

Table 1. Baseline characteristics of patients pre-oxygenated with a high (FiO₂) for PSA in the ED (n=60).

Age in years, median (range)	62 (18-92)
Gender, n (%)	
Female	30 (50)
Male	30 (50)
Cardiovascular Medication use, n (%)	
Beta blocker	10 (16,7)
ACE inhibitor or ATII receptor antagonist	12 (20)
Spironolactone	1 (1,7)
Calcium channel blockers	0 (0)
Known heart failure, n (%)	0 (0)
Pacemaker, n (%)	0 (0)
Abnormality on ECG, n (%)*	3 (5)
ASA classification, n (%)	
I	21 (35)
II	26 (43,4)
III	13 (21,7)
IV	0 (0)
Use of alcohol < 24 hours, n (%)	17 (29,8)

Use of nicotine < 24 hours, n (%)	15 (26,3)
Indication PSA, n (%)	
Reduction dislocation	34 (56,7)
Reduction fracture	8 (13,3)
Incision and drainage abscess	17 (28,3)
Chest tube placement**	1 (1,7)

Legend table 1. ACE, Angiotensin converting enzyme; ATII, angiotensin type 2; ECG, electrocardiogram; ASA, American Society of Anaesthesiologists; PSA, procedural sedation and analgesia. * atrial fibrillation. ** Indication for the chest tube was a large pneumothorax, without signs of hypoxia, or respiratory- or hemodynamic compromise.

Main results

Oxygen administration at a rate of 15L/min during pre-oxygenation resulted in an increase in median oxygen saturation (from 97% to 100%), $p < 0.0001$. Mean CO at baseline was 6.5 (6.0-6.9) L/min, and decreased to 6.3 (5.8-6.8) L/min after 5 minutes of oxygen administration by NRB at a rate of 15L/min, and to 6.2 (5.7-6.7) L/min after a further 5 minutes of flush rate oxygen supplementation ($p=0.037$). Mean SV remained relatively constant, whereas mean SVR increased markedly (table 2).

Table 2. Non-invasively measured (haemodynamic) variables before- and after pre-oxygenation with a high (FiO_2) for PSA in the ED (n=60).

	Baseline N = 60	After 5 minutes NRBM 15L/min N = 60	After 5 minutes flush rate oxygen N = 59	p
SpO ₂ (%)	97 (97 – 98)	100 (100 – 100)*	100 (100 – 100)*	<0.001
CO (L/min)	6.5 (6.0 - 6.9)	6.3 (5.8 - 6.8)	6.2 (5.7 - 6.7)*	0.037
SV (ml)	84 (77 – 89)	83 (75 – 89)	83 (75 – 90)	0.69
SBP (mmHg)	133 (123-151)	138 (125 – 164)*	144 (132 – 162)* ≠	<0.001
HR (bpm)	78 (74 – 81)	76 (72 – 80)	76 (72 – 80)	0.064
SVR (dyn/sec/cm ⁻⁵)	781 (649-1067)	1244 (936 – 1695)*	1337 (988 – 1738)* ≠	<0.001

Legend table 2: Values are mean [95%CI] (CO, SV and HR) or median [IQR] (SpO₂, SBP, and SVR). Represented are P values for repeated measures ANOVA omnibus test. * denotes $p < 0.05$ in post-hoc testing compared to baseline; ≠ denotes $p < 0.05$ compared to 15L/min. CO, cardiac output;; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SpO₂, oxygen saturation; SVR, systemic vascular resistance.

A considerable proportion of the subjects (n=16, 27%) demonstrated a >10% decrease in CO in response to preoxygenation: In about a third of the subjects (n= 5) this was already apparent after the first 5 minutes of preoxygenation with a NRBM at a rate of 15L/min. Baseline patient characteristics were not significantly related to the occurrence of a > 10% decrease in CO (table 3).

Table 3. Patient characteristics stratified by the effect of pre-oxygenation with a high (FiO₂) for PSA in the ED (n=60).

	Patients with a >10 % decrease in CO (n = 16)	Other patients (n = 44)	p
Demographics and history			
Male (n)	5 (31%)	25 (57%)	0.14
Age (years)	67.5 (45.3 – 77.0)	60 (36.3 – 74.5)	0.45
ASA III classification (n)	2 (13%)	11 (25%)	0.48
Use of alcohol <24 hours (n)	5 (31%)	12 (27%)	0.76
Use of nicotine <24 hours (n)	2 (13%)	13 (30%)	0.31
Any cardiovascular medication use (n)	4 (25%)	12 (27%)	1.00
Physical exam			
SpO ₂ (%)	97 (96-99)	97 (97-98)	0.98
HR (bpm)	77 (70-82)	78 (74-82)	0.72
SBP	138 (124-160)	133 (123-149)	0.63
CO (L/min)	6.6 (5.6 – 7.5)	6.4 (5.9 – 7.0)	0.73
SV (ml)	86 (73 – 99)	83 (76 – 90)	0.59
SVR (dyn/sec/cm ⁵)	735 (637 – 1142)	846 (649 – 1042)	0.82

Legend table 3: Values are mean [95% CI] (CO, SV and HR) or median [IQR] (SpO₂, SBP, and SVR). CO, cardiac output; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SpO₂, oxygen saturation; SVR, systemic vascular resistance.

Patients who demonstrated a >10% decrease in CO had a significantly greater increase in SVR (from 735 dyn/sec/cm⁵ at baseline to 1248 dyn/sec/cm⁵ after 15L/min to 1482 dyn/sec/cm⁵ after flush rate oxygen suppletion) compared to other patients (846, 1244 and 1304 dyn/sec/cm⁵ respectively), p=0.025), figure 3 and table 4. Likewise, they demonstrated a significant decrease in SV (from 86 ml

to 80 ml and 76 ml respectively), whereas SV did not decrease in patient who did not demonstrate a clinically relevant decrease in CO (83, 84 and 86 ml respectively, $p < 0.001$).

Table 4. Haemodynamic parameters as a function of oxygen administration, stratified by the response in CO (>10% decrease or < 10% decrease).

	>10% decrease in CO N = 16	Other patients N = 44	p
CO (L/min)			<0.001
Baseline	6.6 (5.6 – 7.5)	6.4 (5.9 – 7.0)	
Oxygen 15L/min	6.2 (5.2 – 7.2)	6.3 (5.7 – 6.9)	
Oxygen Flush rate	5.4 (4.6 – 6.2)	6.5 (5.9 – 7.1)	
SV (ml)			<0.001
Baseline	86 (73 – 99.)	83 (76 – 90)	
Oxygen 15L/min	80 (66 – 95)	84 (76 – 92)	
Oxygen Flush rate	76 (61 – 92)	86 (77 – 94)	
SVR dyn/sec/cm⁵			0.025
Baseline	735 (637 – 1142)	846 (649 – 1042)	
Oxygen 15L/min	1248 (950 – 1954)	1244 (910 – 1658)	
Oxygen Flush rate	1482 (1129 – 2214)	1304 (982 – 1672)	
HR (bpm)			0.85
Baseline	77 (70– 82)	78 (74 – 82)	
Oxygen 15L/min	75 (68 – 81)	77 (72 – 81)	
Oxygen Flush rate	75 (68 – 81)	77 (72 – 82)	
SBP (mmHg)			0.26
Baseline	138 (124 – 160)	133 (123 – 150)	
Oxygen 15L/min	147 (117 – 164)	137 (129 – 164)	
Oxygen Flush rate	148 (127 – 165)	144 (132 – 158)	

Legend table 4. Values are depicted as mean [95%CI] (CO, SV, HR) or median [IQR] (SBP, SVR). Represented P value are for the oxygen dose-to-group interaction in mixed ANOVA. T=5; value after 5 minutes of oxygen administration by NRBM at a rate of 15L/min; T=10; value after an additional 5 minutes of oxygen administration by NRBM at flush rate. CO, cardiac output; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SVR, systemic vascular resistance.

Discussion

In this study, we found that a short 10-minute exposure to a high FiO₂ is associated with a significant drop in mean CO. This stresses the importance of titrated oxygen administration in the ED and in prehospital care.

1
2
3 The observed drop in mean CO in this study is in line with previous literature, wherein it has been
4 shown that prolonged exposure to a high FiO₂ has a negative effect on CO (13-16), and (ultimately)
5 on morbidity and mortality (23). The proposed pathophysiological mechanism mediating the relation
6 between hyperoxia and CO is coronary vasoconstriction (13-16), resulting in a decrease in SV. The
7 latter is in line with our finding that SV decreased with >10% in subjects who demonstrated a >10%
8 decrease in their CO, whereas HR remained unchanged. In these patients we also observed a marked
9 increase in SVR (afterload), which may also have contributed to the reduction in CO. Although this
10 may be the result of an increased sympathetic tone due to pain and/or stress, we did not observe a
11 concomitant increase in HR. Alternatively, free oxygen radicals have been shown to modulate the tone
12 of vascular smooth muscle both directly and indirectly by affecting the production- or biological
13 activity of vasoactive mediators (24,25). Furthermore, free radicals have the potential to damage
14 (mitochondrial) DNA, lipids and proteins, and may cause irreversible damage (23,26-28). However, we
15 can only speculate about the exact aetiology and the relative contribution of the above mentioned
16 processes however, as we did not measure free oxygen radicals and/or oxidative stress in our study.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37 One in four patients demonstrated a >10% drop in CO. Changes of this magnitude might be of
38 relevance to patients who have an already decreased baseline CO. It is worth mentioning however,
39 that not only the magnitude- but also the duration of the drop are relevant for the ultimate effect. As
40 per protocol medication for PSA was administered after the second period of pre-oxygenation, we
41 could not monitor (speed of) recovery of CO in our current study, and therefore future studies should
42 focus on reversibility of the observed changes.

43
44
45
46
47
48
49
50
51
52 As 1 in 4 patients demonstrates a >10% drop in CO, it seems reasonable to titrate oxygen
53 administration on SpO₂ in all patients, especially in patients with an already compromised circulation,
54 and even when oxygen is only administered for a short duration of time, as in the prehospital setting,
55 or in ED. This can be achieved relatively easily when oxygen is administered for the purpose of treating-

1
2
3 or preventing hypoxia, but it is more difficult to achieve when oxygen is administered for the purpose
4
5 of denitrogenation preceding PSA or RSI. In those instances, the risk of short duration hyperoxia should
6
7 be balanced against the risk of the occurrence of hypoxic episodes when pre-oxygenation with a high
8
9 FiO_2 is not provided: Although negative effects on CO are undesirable in patients undergoing PSA or
10
11 RSI (who receive drugs affecting vascular tone and cardiac contractility), the risk of hypoxic episodes
12
13 probably outweighs this risk in these patients.
14
15
16

17
18 Ideally, one should aim for a high SpO_2 but at the same time avoid a (too) high PaO_2 . As continuous
19
20 blood gas analysis is normally not feasible or appropriate in the prehospital- or ED setting, future
21
22 studies should investigate if there is a role for non-invasive tools to quantify (and prevent) hyperoxia,
23
24 for example by estimating the oxygen reserve index (29,30).
25
26
27
28
29

30 **Limitations**

31
32 Our study has several limitations, inherent to the study design. First, although we observed lower CO
33
34 and higher SVR values with flush-rate oxygen administration than with 15L/min, we cannot exclude
35
36 that this is a time-dependent rather than a dose dependent effect, as flush rate oxygen was
37
38 administered immediately after 5 minutes of 15L/min were administered. Second, we did not perform
39
40 arterial blood gas analysis after pre-oxygenation to establish the presence (and the amount of)
41
42 hyperoxia. However, the presence of hyperoxemia is highly likely, as SpO_2 increased to 100% in all
43
44 participating subjects, and previous studies with comparable oxygen administration strategies have
45
46 demonstrated the presence of both a high expired oxygen fraction (3, 31) and a high PaO_2 . In addition,
47
48 14 patients had to be excluded as no reliable ClearSight® signal could be obtained, sometimes for
49
50 unknown reasons, which could have contributed to selection bias. Also, at least a quarter of the
51
52 patients used alcohol (n=15) or nicotine (n=17) in the last 24 hours. Since chronic abuse of nicotine
53
54 and/or alcohol can lead to cardiovascular impairment, for example by decreasing coronary blood flow,
55
56 this could also be a confounding factor (32,33). Finally, generalizability of our results is limited due to
57
58
59
60

1
2
3 the selection of our study population: None of our patients had significant cardiovascular co-
4 morbidity. Therefore no conclusions can be drawn regarding how hyperoxia would affect patients with
5 heart failure, especially when they already have a compromised CO.
6
7
8
9
10
11
12
13
14

15 **Conclusion**

16
17 Exposure of patients to a high FiO₂ for 5-10 minutes results in a significant drop in CO in 1 out of 4
18 patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited
19 amount of time, FiO₂ should be titrated based on deficit and high flow oxygen should not be given as
20 a routine treatment.
21
22
23
24
25
26
27
28
29

30 **Acknowledgments:** We want to thank dr. Jack J.M. Ligtenberg for his guidance and discussions during
31 this study. We also want to thank all the residents of the Medical Centre Leeuwarden for their help
32 with the inclusion of patients.
33
34
35
36
37
38

39 **Declarations**

40
41 Competing interests: The authors declare that they have no competing interests.
42
43

44
45 Funding: This work was financially supported by the MCL Research academy (purchase of the finger
46 cuffs). The ClearSight® system was made available at no costs by Edward Lifesciences. Funding
47 institutions had no role in conception, design, or conduct of the study; collection, management,
48 analysis, interpretation, or presentation of the data; or preparation, review, or approval of the
49 manuscript. Award/grant number not applicable.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Ethics approval and consent to participate: Regionale toetsingscommissie patiëntgebonden
4
5 onderzoek (RTPO) Leeuwarden, protocol number nWMO 270. Written consent to participate was
6
7 obtained.
8
9

10
11 Consent for publication: not applicable.
12
13

14
15 Availability of data and materials: The datasets used and/or analyzed during the current study are
16
17 available from the corresponding author on reasonable request.
18
19

20
21
22 Author's contributions: All authors fulfilled the ICMJE criteria for authorship. RS and EtA conceived the
23
24 study. Evl, RS and EtA acquired and interpreted the data. RS and EtA drafted the manuscript. All
25
26 authors revised the manuscript critically and gave final approval to submission of the manuscript.
27
28
29
30
31
32

33 **References**

- 34 (1) ACEP Clinical policy for procedural sedation and analgesia in the emergency department.
35 AnnEmergMed 1998;663-77.
36
37 (2) American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non
38 Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists.
39 Anesthesiology. 2002;96:1004-17/1996;84:458-71.
40
41 (3) Thomson D, Cowan T, Loten C, Botfield C, Holliday E, Attia J. High-flow oxygen in patients
42 undergoing procedural sedation in the emergency department: A retrospective chart review. Emerg
43 Med Australas 2017 Feb;29(1):33-39.
44
45 (4) Driver BE, Prekker ME, Kornas RL, Cales EK, Reardon RF. Flush Rate Oxygen for Emergency Airway
46 Preoxygenation. Ann Emerg Med 2017 Jan;69(1):1-6 .
47
48 (5) Bouroche G, Bourgain J. Preoxygenation and general anesthesia: a review. Minerva Anesthesiol
49 2015; 81(8): 910-20.
50
51 (6) Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, et al. Arterial hyperoxia and
52 mortality in critically ill patients: a systematic review and meta-analysis. Crit Care 2014 Dec
53 23;18(6):711-014-0711-x
54
55
56
57
58
59
60

- 1
2
3 (7) Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of Conservative vs
4 Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-
5 ICU Randomized Clinical Trial. *JAMA* 2016 Oct 18;316(15):1583-1589.
6
7
8 (8) de Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PH, et al. Association
9 between administered oxygen, arterial partial oxygen pressure and mortality in mechanically
10 ventilated intensive care unit patients. *Crit Care* 2008;12(6):R156.
11
12 (9) Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, et al. Association between
13 arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA* 2010
14 Jun 2;303(21):2165-2171.
15
16 (10) Eastwood G, Bellomo R, Bailey M, Taori G, Pilcher D, Young P, et al. Arterial oxygen tension and
17 mortality in mechanically ventilated patients. *Intensive Care Med* 2012 Jan;38(1):91-98.
18
19 (11) Gao Z, Spilk S, Momen A, et al. Vitamin C prevents hyperoxia-mediated coronary
20 vasoconstriction and impairment of myocardial infarction in healthy subjects. *Eur J Appl Physiol*
21 2012; 112(2): 483-92.
22
23 (12) Mak S, Egri Z, Tanna G, et al. Vitamin C prevents hyperoxia-mediated vasoconstriction and
24 impairment of endothelium-dependent vasodilation. *Am J Physiol Heart Circ Physiol* 2002; 282(6):
25 H2414-21.
26
27 (13) Haque WA, Boehmer J, Clemson BS, Leuenberger UA, Silber DH, Sinoway LI. Hemodynamic
28 effects of supplemental oxygen administration in congestive heart failure. *J Am Coll Cardiol* 1996
29 Feb;27(2):353-357.
30
31 (14) Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling
32 pressures in patients with and without congestive heart failure. *Chest* 2001 Aug;120(2):467-473.
33
34 (15) McNulty PH, King N, Scott S, Hartman G, McCann J, Kozak M, et al. Effects of supplemental
35 oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. *Am J*
36 *Physiol Heart Circ Physiol* 2005 Mar;288(3):H1057-62.
37
38 (16) Rousseau A, Bak Z, Janerot-Sjoberg B, Sjoberg F. Acute hyperoxaemia-induced effects on
39 regional blood flow, oxygen consumption and central circulation in man. *Acta Physiol Scand* 2005
40 Mar;183(3):231-240.
41
42 (17) Leitch P, Hudson A, Griggs J, et al. Incidence of hyperoxia in trauma patients receiving pre-
43 hospital emergency anaesthesia: results of a 5-year retrospective analysis. *Scand J Trauma Resusc*
44 *Emerg Med* 2021; 29(1): 134.
45
46 (18) Ameloot K, van de Vijver K, Broch O, et al. Nexfin noninvasive hemodynamic monitoring:
47 validation against continuous pulse contour and intermittent transpulmonary thermodilution
48 derived cardiac output in critically ill patients. *ScientificWorldJournal*. 2013 Nov 11;2013:519080.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (19) Boisson M, Poignard M, Pontier B, et al. Cardiac output monitoring with thermodilution pulse-
4 contour analysis vs. non-invasive pulse-contour analysis. *Anaesthesia* 2019;74(6):735-740.
5
6 (20) Delaney L, Bellomo R, van Haren F. Responsiveness of non-invasive continuous cardiac output
7 monitoring during the valsalva maneuver. *Clin Nurs Res* 2020; 29(2): 127-132.
8
9 (21) de Wilde R, Schreuder J, van den Berg P, et al. An evaluation of cardiac output by five arterial
10 pulse contour techniques during cardiac surgery. *Anaesthesie* 2007; 62(8): 760-8.
11
12 (22) Hall, J. E. (2011). *Guyton and Hall textbook of medical physiology* (12th ed.). New York: Elsevier
13
14 (23) Stolmeijer R, Bouma HR, Zijlstra JG, et al. A systematic review of the effects of hyperoxia in
15 acutely ill patients: should we aim for less? *Biomed Res Int* 2018;
16
17 <https://doi.org/10.1155/2018/7841295>.
18
19 (24) Rubanyi G. Vascular effects of oxygen-derived free radicals. *Free Radic Biol Med* 1988;4(2):107-
20 20.
21
22 (25) Smit B, Smulders YM, Eringa EC, et al. Effects of hyperoxia on vascular tone in animal models:
23 systematic review and meta-analysis. *Critical Care* 2018: [https://doi.org/10.1186/s13054-018-2123-](https://doi.org/10.1186/s13054-018-2123-9)
24 9.
25
26 (26) D'Aquila P, Bellizzi D, Passarino G. Mitochondria in health, aging and diseases: the epigenetic
27 perspective. *Biogerontology*. 2015;16(5):569-85.
28
29 (27) Granata S, Dalla Gassa A, Tomei P, et al. Mitochondria: a new therapeutic target in chronic
30 kidney disease. *Nutrition & metabolism*. 2015;12:49.
31
32 (28) Wang Y, Hekimi S. Mitochondrial dysfunction and longevity in animals: Untangling the knot.
33 *Science*. 2015;350(6265):1204-7.
34
35 (29) Scheeren T, Belda F, Perel A. The oxygen reserve index (ORI): a new tool to monitor oxygen
36 therapy. *J Clin Monit Comput* 2018;32(3):379-389.
37
38 (30) Vos J, Willems H, van Amsterdam K, et al. Oxygen reserve index: validation of a new variable.
39 *Anesth Analg* 2019;129(2):409-415.
40
41 (31) Driver B, Prekker M, Komars R, et al. Flush rate oxygen for emergency airway preoxygenation.
42 *Ann Emerg Med* 2017; 69(1): 1-6.
43
44 (32) Kenneth J, Mukamal M. The effects of smoking and drinking on cardiovascular disease and risk
45 factors. *Alcohol Res Health* 2006; 29(3): 199-202.
46
47 (33) Jalali Z, Khademalhosseini M, Soltani N, et al. Smoking, alcohol and opioids effect on coronary
48 microcirculation: an update overview. *BMC Cardiovasc Disord* 2021; 21: 185.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figures:**
4
5
6


7 **Figure 1.** Study Overview
8

9 *Legend Figure 1: Arrows indicate moments of measurement of haemodynamic parameters.*
10
11
12

13
14
15 **Figure 2.** Patient inclusion
16
17
18
19
20


21 **Figure 3.** Boxplots of stroke volume (SV) and systemic vascular resistance (SVR) as a function of
22 oxygen administration in the emergency department (ED), stratified by response in CO (>10%
23 decrease or < 10% decrease).
24
25


26
27 *Legend figure 3: Represented are median, IQR and ranges (with outliers). Grey boxes represent subjects with a*
28 *> 10% decrease in CO (n=16). White boxes represent subjects with a <10% decrease in CO during the course of*
29 *the pre-oxygenation (n=44). Times on the x-axis are baseline, after 5 minutes and after 10.*
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Patient inclusion



For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	4	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7	
Bias	9	Describe any efforts to address potential sources of bias	6-7	
Study size	10	Explain how the study size was arrived at	7	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	7-8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8-9
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-12

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Haemodynamic effects of a 10-minute treatment with a high inspired oxygen concentration in the Emergency Department: a prospective observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059848.R1
Article Type:	Original research
Date Submitted by the Author:	09-May-2022
Complete List of Authors:	Stolmeijer, Renate; University Medical Centre Groningen, Department of Emergency Medicine VAN IEPEREN, Ellen; Medical Centre Leeuwarden, Department of Emergency Medicine LAMEIJER, Heleen; Medical Centre Leeuwarden, Department of Emergency Medicine VAN BEEST, Paul; Medical Centre Leeuwarden, Department of Anaesthesiology ter Maaten, Jan; University Medical Centre Groningen, Emergency Department, Department of internal medicine ter Avest, Ewoud; University Medical Centre Groningen
Primary Subject Heading:	Emergency medicine
Secondary Subject Heading:	Anaesthesia
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Adult intensive & critical care < ANAESTHETICS, INTENSIVE & CRITICAL CARE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Haemodynamic effects of a 10-minute treatment with a high inspired oxygen concentration in the**
4
5 **Emergency Department: a prospective observational study.**
6
7
8
9

10 Renate STOLMEIJER¹, Ellen VAN IEPEREN², Heleen LAMEIJER², Paul VAN BEEST³, Jan C. TER
11
12 MAATEN⁴, Ewoud TER AVEST^{1,5}.
13
14
15

16 ¹ Department of Emergency Medicine, University Medical Centre Groningen, the Netherlands.
17

18 ² Department of Emergency Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
19

20 ³ Department of Anaesthesiology, Medical Centre Leeuwarden, the Netherlands.
21

22 ⁴ Department of Internal Medicine, University Medical Centre Groningen, the Netherlands.
23

24 ⁵ HEMS, Kent, Surrey and Sussex Air Ambulance Trust, Redhill, Surrey, United Kingdom.
25
26
27
28
29

30 **Correspondence to:**

31
32 Renate Stolmeijer, MD: t.m.stolmeijer@umcg.nl
33
34
35
36

37 **Short title:** The effects of short term hyperoxia on cardiac output in the ED.
38
39
40

41 **Word count:** 3786
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Previous studies show that prolonged exposure to a high inspired oxygen concentration (FiO_2) is associated with unfavourable hemodynamic effects. Until now, it is unknown if similar effects also occur after oxygen therapy of limited duration in the emergency department (ED).

Objectives. To investigate the hemodynamic effects of a high FiO_2 administered for a limited duration of time in patients who receive preoxygenation for procedural sedation and analgesia (PSA) in the ED.

Design, settings and participants. In a prospective cohort study, cardiac output (CO), stroke volume (SV) and systemic vascular resistance (SVR) were measured using the ClearSight® non-invasive CO monitoring system in patients who received preoxygenation for PSA in the ED. Measurements were performed at baseline, after 5 minutes of preoxygenation via a non-rebreathing mask at 15/L min and after 5-minutes of flush rate oxygen administration.

Outcomes measures. The primary outcome was defined as the change in CO (L/min) from baseline after subsequent preoxygenation with 15L/min and flush rate.

Results. Sixty patients were included. Mean CO at baseline was 6.5 (6.0-6.9)L/min and decreased to 6.3 (5.8-6.8) L/min after 5 minutes of oxygen administration at a rate of 15L/min, and to 6.2 (5.7-6.70) L/min after another 5 minutes at flush rate ($p=0.037$). Mean SV remained relatively constant during this period, whereas mean SVR increased markedly (from 781 [649-1067], to 1244 [936-1695] to 1337 [988-1738] dyn/sec/cm⁻⁵, $p<0.001$). Sixteen (27%) patients experienced a >10% decrease in CO.

Conclusion. Exposure of patients to a high FiO_2 for 5-10 minutes results in a significant drop in CO in 1 out of 4 patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited amount of time, FiO_2 should be titrated based on deficit whenever this is feasible and high flow oxygen should not be given as a routine treatment.

Key words: hyperoxia, inspired oxygen concentration, hyperoxemia, emergency department, oxygen therapy, procedural sedation and analgesia.

Strengths and limitations of this study:

- This prospective study investigates the hemodynamic effects of treatment of patients in the emergency department with a high inspired oxygen concentration for a limited duration of time (10 minutes).
- Non-invasive monitoring of cardiac output, stroke volume and systemic vascular resistance was used before- and during pre-oxygenation to quantify hemodynamic effects.
- Generalizability this study is limited due to relative homogeneity of the subjects included in the study.

Background

Oxygen is frequently administered in the Emergency Department (ED) and in the prehospital setting by emergency medical services (EMS). It is used both to treat or prevent hypoxia in acutely ill patients and to pre-oxygenate (de-nitrogenate) patients for procedures such as rapid sequence induction (RSI) or procedural sedation and analgesia (PSA), (1-3). Often, oxygen is administered at a flow of 15 L/min or even higher (4) via a non-rebreathing mask (NRBM) in order to increase the end-expiratory oxygen fraction, and to de-nitrogenate the lungs, thereby increasing the safe apnea time for PSA or RSI (5).

Oxygen administration however, may not be without risk. Previous studies show that prolonged exposure to a high inspired oxygen concentration (FiO_2) is associated with higher mortality rates in patients hospitalised with various conditions (6-10). This may be explained by a negative effect on cardiac output (CO), mediated by peripheral and coronary vasoconstriction, resulting from direct effects of oxygen on smooth muscle tone (11,12), and by the formation of reactive oxygen species that contribute to (vascular) oxidative stress (13-16).

1
2
3
4
5
6 As opposed to hospitalised patients, patients in the prehospital setting and in the ED normally receive
7 high-flow oxygen only for a limited amount of time. Previous studies show nonetheless that this results
8 in significant hyperoxemia in many patients (17). The clinical relevance of this however is largely
9 unknown, as until now the hemodynamic effects of exposure of patients in the ED to a high FiO_2 for
10 only a limited duration of time have never been reported.
11
12
13
14
15
16
17
18
19
20

21 Therefore, in the present study, we aim to investigate the hemodynamic effects of a high FiO_2
22 administered for only a limited duration of time in patients who receive preoxygenation for PSA in the
23 ED.
24
25
26
27
28
29

30 **Methods**

31 Study Setting and Design

32 A single centre prospective study was performed in a cohort of patients undergoing pre-oxygenation
33 for PSA in the ED of the Medical Centre Leeuwarden (a teaching hospital in the Netherlands with an
34 27.000 ED visits yearly) between May 2018 to June 2019 (ClinicalTrials.gov (NCT03930979). Ethical
35 approval was sought and obtained from the ethical committee of the RTPO Leeuwarden (protocol
36 number nWMO 270).
37
38
39
40
41
42
43
44
45
46
47

48 Patient and public involvement

49 No patients were involved in the design, recruitment or conduct of this study.
50
51
52
53
54

55 Study population

56 Patients were eligible for inclusion in the study if they were older than 18 years and were about to
57 receive PSA to facilitate a procedure in ED. Patients were excluded if PSA was needed immediately
58
59
60

1
2
3 according to the treating physician (no time to obtain informed consent and/or to perform necessary
4 calibration of the system used to measure CO), if they were pregnant, if they presented with
5 significant hypoxia (defined as an oxygen saturation <90% or a pO₂ < 8.0 kPa), if they received oxygen
6 suppletion pre-inclusion, if they had chronic obstructive pulmonary disease (COPD) GOLD I or II with
7 hypercapnia (pCO₂ >6.4 kPa) or COPD GOLD III or IV, if they used bleomycine, if they presented with
8 a cardiogenic shock (SBP <90 mmHg) or if they needed PSA for electrocardioversion- or pacing (for
9 reasons of difficulty obtaining a reliable signal to measure CO). Patients could only be included once.
10
11
12
13
14
15
16
17
18
19
20
21

22 Study protocol

23
24 After informed consent was obtained from eligible patients, demographics, medical history and
25 medication use, ECG at presentation and vital signs were obtained. Subsequently, the ClearSight® non-
26 invasive cardiac output measurement system was attached to the patient and calibrated for
27 continuous monitoring of blood pressure, CO, SV and SVR. Baseline values for these parameters were
28 established as an average of three repeated measurements. Thereafter, oxygen was administered via
29 a NRBM at a rate of 15L/min from a powered wall source, and measurements (CO, CI, SV, and SVR)
30 were repeated after 5 minutes. Thereafter, the rate of oxygen administration was increased to flush
31 rate (30L/min) and after 5 minutes measurements were repeated. No other interventions than oxygen
32 administration were performed during this period, and no medication or intravenous fluids were
33 administered. Thereafter, care as usual was provided for the conduct of PSA. (figure 1)
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Data collection

50
51 The following parameters were collected on a dedicated Case Report Form (CRF) for all included
52 patients: patient demographics including (cardiac) medical history and alcohol- nicotine- and
53 medication use, ECG abnormalities at presentation, ASA classification and indication for PSA, and vital
54 parameters (heart rate (HR), non-invasively measured systolic blood pressure (SBP), oxygen saturation
55 (SpO₂), CO, SV and SVR).
56
57
58
59
60

Non-invasive cardiac output measurements

CO was measured non-invasively using The ClearSight® system (Edwards Lifesciences). The methodology of the ClearSight® is based on Nexfin technology. This consists of pulsatile unloading of the finger arterial walls using an inflatable finger cuff with a built-in photoelectric plethysmograph that uses pressure to maintain a constant blood volume in the finger. ClearSight® calculates beat-to-beat SV by dividing the area under the SBP curve (measured at 200 Hz) by the aortic input impedance (Zin). The value of Zin is determined from a three-element Windkessel model in which the nonlinear effect of MAP and the influence of the patient's age, height, weight, and gender on aortic mechanical properties are incorporated. Because the waveform at the finger shows a more undulatory appearance than the radial pressure waveform, the system transforms the finger waveform into a brachial waveform with a specific filter. ClearSight® uses the integrated area under the pulsatile systolic waveform from the brachial pressure wave as an input to the model, which directly yields SV and produces CO by multiplying beat-to-beat SV by instantaneous heart rate. The Nexfin technology used in the ClearSight® is validated in multiple studies (18,19). All investigators received training given by a trainer of the manufacturer of ClearSight® in how to operate the device before they were able to include patients for this study.

Outcomes

The primary outcome was defined as the absolute change in CO from baseline after respectively 5 minutes 15L O₂/min and 5 minutes flush rate oxygenation via a NRBM.

Secondary outcomes were defined as:

- The absolute change in HR, SBP, SV and SVR from baseline after respectively 15L O₂/min and flush rate oxygenation via NRBM.
- The number of subjects demonstrating a >10% change in CO* in response to oxygen

1
2
3 administration (both 15L/min and Flush rate).
4
5

6
7
8 * a 10% change in CO was deemed clinically relevant as this corresponds to the effect of a Valsalva
9 manoeuvre (20) and has been shown to be a detectable change using a (non-invasive) method based
10 on pulse contour analysis (21).
11
12
13

14 15 16 17 18 19 Sample size

20 Based on previous literature (22) it was estimated that with a mean (SD) CO of 6.0 (0.8) L/min, 54
21 patients are necessary to allow the detection of a 10% decrease in CO as a result of procedural
22 sedation with a power of 90% and a type I error rate of 5%. To allow for an attrition rate of 10 % we
23 aimed to include 60 patients.
24
25
26
27
28
29

30 31 32 33 Statistical analysis

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Continues variables are represented as mean (95% CI) or median (IQR) where appropriate. Repeated
measures ANOVA with Greenhouse Geiser correction and post-hoc testing (Tukey Kramer) was used
to analyze the difference in hemodynamic measurements at baseline and after preoxygenation with
NRBM 15L/min and flush rate oxygen. Comparisons between patients demonstrating a > 10% decrease
in CO and those who did not were made using Student's t-test, Mann-Whitney U test, or Fisher's exact
test where appropriate. Mixed ANOVA was used to calculate oxygen dose-to-group interactions for
these groups. Missing data was reported in the results section according to the STROBE guideline. A
 p -value <0.05 was considered statistically significant. All statistical analysis were done with SPSS 23.0
for Apple statistical package (SPSS Inc, Chicago, Illinois, USA) and Vassarstats statistical software (Vassar
college, Poughkeepsie, New York, USA).

Results

Characteristics of study population

During the study period, a total of 91 patients were screened for eligibility. Thirty-one patients were excluded after screening due to various reasons (figure 2). Fourteen patients were excluded as no reliable signal for cardiac output monitoring could be obtained. In 6/14 patients this was due to identifiable patient factors (cold hands, tremor), whereas in the remaining 8 patients the system software failed.

Baseline characteristics of the study population are shown in table 1. Median (range) age of the included subjects was 62 (18-92) years, with an equal gender distribution. A total of 16 patients (26,7%) used one or more cardiovascular drugs on a daily basis. There were no patients with pre-existent heart failure or a pacemaker in situ. Other patient characteristics, and vital signs at presentation are represented in table 1. None of the patients received intravenous fluids before arrival in hospital. Sometimes they did receive analgesics administered by EMS; fentanyl (n=25 (41,7%)), ketamine (n=12 (20%)) or other opioids (n=4 (6,7%)).

Table 1. Baseline characteristics of patients pre-oxygenated with a high (FiO₂) for PSA in the ED (n=60).

Age in years, median (range)	62 (18-92)
Gender, n (%)	
Female	30 (50)
Male	30 (50)
Cardiovascular Medication use, n (%)	
Beta blocker	10 (16,7)
ACE inhibitor or ATII receptor antagonist	12 (20)

Spironolactone	1 (1,7)
Calcium channel blockers	0 (0)
Known heart failure, n (%)	0 (0)
Pacemaker, n (%)	0 (0)
Abnormality on ECG, n (%)*	3 (5)
ASA classification, n (%)	
I	21 (35)
II	26 (43,3)
III	13 (21,7)
IV	0 (0)
Use of alcohol < 24 hours, n (%)	17 (29,8)
Use of nicotine < 24 hours, n (%)	15 (26,3)
Indication PSA, n (%)	
Reduction dislocation	34 (56,7)
Reduction fracture	8 (13,3)
Incision and drainage abscess	17 (28,3)
Chest tube placement**	1 (1,7)

Legend table 1. ACE, Angiotensin converting enzyme; ATII, angiotensin type 2; ECG, electrocardiogram; ASA, American Society of Anaesthesiologists; PSA, procedural sedation and analgesia. * atrial fibrillation. ** Indication for the chest tube was a large pneumothorax, without signs of hypoxia, or respiratory- or hemodynamic compromise.

Main results

Oxygen administration at a rate of 15L/min during pre-oxygenation resulted in an increase in median oxygen saturation (from 97% to 100%), $p < 0.0001$. Mean (95% CI) CO at baseline was 6.5 (6.0-6.9) L/min, and decreased to 6.3 (5.8-6.8) L/min after 5 minutes of oxygen administration by NRB at a rate of 15L/min, and to 6.2 (5.7-6.7) L/min after a further 5 minutes of flush rate oxygen supplementation ($p=0.037$). Mean SV remained relatively constant, whereas mean SVR increased markedly (table 2).

Table 2. Non-invasively measured (haemodynamic) variables before- and after pre-oxygenation with a high (FiO₂) for PSA in the ED (n=60).

	Baseline N = 60	After 5 minutes NRBM 15L/min N = 60	After 5 minutes flush rate oxygen N = 59	p
SpO ₂ (%)	97 (97 – 98)	100 (100 – 100)*	100 (100 – 100)*	<0.001
CO (L/min)	6.5 (6.0 - 6.9)	6.3 (5.8 - 6.8)	6.2 (5.7 - 6.7)*	0.037
SV (ml)	84 (77 – 89)	83 (75 – 89)	83 (75 – 90)	0.69
SBP (mmHg)	133 (123-151)	138 (125 – 164)*	144 (132 – 162)* ≠	<0.001
HR (bpm)	78 (74 – 81)	76 (72 – 80)	76 (72 – 80)	0.064
SVR (dyn/sec/cm ⁻⁵)	781 (649-1067)	1244 (936 – 1695)*	1337 (988 – 1738)* ≠	<0.001

Legend table 2: Values are mean [95%CI] (CO, SV and HR) or median [IQR] (SpO₂, SBP, and SVR). Represented are P values for repeated measures ANOVA omnibus test. * denotes p<0.05 in post-hoc testing compared to baseline; ≠ denotes p<0.05 compared to 15L/min. CO, cardiac output;; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SpO₂, oxygen saturation; SVR, systemic vascular resistance.

A considerable proportion of the subjects (n=16, 27%) demonstrated a >10% decrease in CO in response to preoxygenation: In about a third of the subjects (n= 5) this was already apparent after the first 5 minutes of preoxygenation with a NRBM at a rate of 15L/min. Baseline patient characteristics were not significantly related to the occurrence of a > 10% decrease in CO (table 3).

Table 3. Baseline patient characteristics stratified by the effect of pre-oxygenation with a high (FiO₂) for PSA in the ED (n=60).

	Patients with a >10 % decrease in CO (n = 16)	Other patients (n = 44)	p
Demographics and history			
Male (n)	5 (31%)	25 (57%)	0.14
Age (years)	67.5 (45.3 – 77.0)	60 (36.3 – 74.5)	0.45
ASA III classification (n)	2 (13%)	11 (25%)	0.48
Use of alcohol <24 hours (n)	5 (31%)	12 (27%)	0.76
Use of nicotine <24 hours (n)	2 (13%)	13 (30%)	0.31
Any cardiovascular medication use (n)	4 (25%)	12 (27%)	1.00
Physical exam			
SpO ₂ (%)	97 (96-99)	97 (97-98)	0.98
HR (bpm)	77 (70-82)	78 (74-82)	0.72
SBP	138 (124-160)	133 (123-149)	0.63
CO (L/min)	6.6 (5.6 – 7.5)	6.4 (5.9 – 7.0)	0.73
SV (ml)	86 (73 – 99)	83 (76 – 90)	0.59
SVR (dyn/sec/cm ⁻⁵)	735 (637 – 1142)	846 (649 – 1042)	0.82

Legend table 3: Values are mean [95% CI] (CO, SV and HR) or median [IQR] (SpO₂, SBP, and SVR). CO, cardiac output; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SpO₂, oxygen saturation; SVR, systemic vascular resistance.

Patients who demonstrated a >10% decrease in CO had a significantly greater increase in SVR (from 735 dyn/sec/cm⁻⁵ at baseline to 1248 dyn/sec/cm⁻⁵ after 15L/min to 1482 dyn/sec/cm⁻⁵ after flush rate oxygen supplementation) compared to other patients (846, 1244 and 1304 dyn/sec/cm⁻⁵ respectively), p=0.025), figure 3 and table 4. Likewise, they demonstrated a significant decrease in SV (from 86 ml to 80 ml and 76 ml respectively), whereas SV did not decrease in patient who did not demonstrate a clinically relevant decrease in CO (83, 84 and 86 ml respectively, p<0.001).

Table 4. Haemodynamic parameters as a function of oxygen administration, stratified by the response in CO (>10% decrease or < 10% decrease).

	>10% decrease in CO	Other patients	p
	N = 16	N = 44	

CO (L/min)				<0.001
	Baseline	6.6 (5.6 – 7.5)	6.4 (5.9 – 7.0)	
	Oxygen 15L/min	6.2 (5.2 – 7.2)	6.3 (5.7 – 6.9)	
	Oxygen Flush rate	5.4 (4.6 – 6.2)	6.5 (5.9 – 7.1)	
SV (ml)				<0.001
	Baseline	86 (73 – 99.)	83 (76 – 90)	
	Oxygen 15L/min	80 (66 – 95)	84 (76 – 92)	
	Oxygen Flush rate	76 (61 – 92)	86 (77 – 94)	
SVR dyn/sec/cm⁵)				0.025
	Baseline	735 (637 – 1142)	846 (649 – 1042)	
	Oxygen 15L/min	1248 (950 – 1954)	1244 (910 – 1658)	
	Oxygen Flush rate	1482 (1129 – 2214)	1304 (982 – 1672)	
HR (bpm)				0.85
	Baseline	77 (70– 82)	78 (74 – 82)	
	Oxygen 15L/min	75 (68 – 81)	77 (72 – 81)	
	Oxygen Flush rate	75 (68 – 81)	77 (72 – 82)	
SBP (mmHg)				0.26
	Baseline	138 (124 – 160)	133 (123 – 150)	
	Oxygen 15L/min	147 (117 – 164)	137 (129 – 164)	
	Oxygen Flush rate	148 (127 – 165)	144 (132 – 158)	

Legend table 4. Values are depicted as mean [95%CI] (CO, SV, HR) or median [IQR] (SBP, SVR). Represented P value are for the oxygen dose-to-group interaction in mixed ANOVA. T=5; value after 5 minutes of oxygen administration by NRBM at a rate of 15L/min; T=10; value after an additional 5 minutes of oxygen administration by NRBM at flush rate. CO, cardiac output; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SVR, systemic vascular resistance.

Discussion

1
2
3 In this study, we found that a short 10-minute exposure to a high FiO_2 is associated with a significant
4 drop in mean CO. This stresses the importance of titrated oxygen administration in the ED and in
5 prehospital care whenever this is feasible: Clinicians should carefully balance the risk of hyperoxia
6 against the risk of hypoxia when oxygen is administered, especially in patients with already
7 compromised circulation.
8
9
10
11
12
13
14
15
16

17 The observed drop in mean CO in this study is in line with previous literature which show that
18 prolonged exposure to a high FiO_2 has a negative effect on CO (13-16), and (ultimately) on morbidity
19 and mortality (23). The proposed pathophysiological mechanism mediating the relation between
20 hyperoxia and CO is coronary vasoconstriction (13-16), resulting in a decrease in SV. The latter is in
21 line with our finding that SV decreases with >10% in subjects who demonstrated a >10% decrease in
22 their CO, whereas HR remained unchanged. In these patients we also observed a marked increase in
23 SVR (afterload), which may have contributed to the reduction in CO. Although this may be the result
24 of an increased sympathetic tone due to pain and/or stress, we did not observe a concomitant
25 increase in HR. Alternatively, free oxygen radicals have been shown to modulate the tone of vascular
26 smooth muscle both directly and indirectly by affecting the production- or biological activity of
27 vasoactive mediators (24,25). Furthermore, free radicals have the potential to damage
28 (mitochondrial) DNA, lipids and proteins, and may cause irreversible damage (23,26-28). However, we
29 can only speculate about the exact aetiology and the relative contribution of the above mentioned
30 processes, as we did not measure free oxygen radicals and/or oxidative stress in our study.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 One in four patients demonstrated a >10% drop in CO. Changes of this magnitude might be of
51 relevance to patients who already have a decreased baseline CO. It is worth mentioning however, that
52 not only the magnitude, but also the duration of the drop are relevant for the ultimate effect. As
53 medication for PSA was administered per protocol after the second period of pre-oxygenation, we
54
55
56
57
58
59
60

1
2
3 could not monitor (speed of) recovery of CO in our current study, and therefore future studies should
4
5 focus on reversibility of the observed changes.
6
7
8
9

10 As 1 in 4 patients demonstrates a >10% drop in CO, it seems reasonable to titrate oxygen
11 administration on SpO₂ in patients, especially in patients with an already compromised circulation,
12 even when oxygen is only administered for a short duration of time, as in the prehospital setting or in
13 ED. This can be achieved relatively easy when oxygen is administered for the purpose of treating or
14 preventing hypoxia. But it is more difficult to achieve when oxygen is administered for the purpose of
15 denitrogenation preceding PSA or RSI and thereby increasing save apnoeic time. In those instances,
16 the risk of short duration hyperoxia should be balanced against the risk of the occurrence of hypoxic
17 episodes when pre-oxygenation with a high FiO₂ is not provided. Although negative effects on CO are
18 undesirable in patients undergoing PSA or RSI (who receive drugs affecting vascular tone and cardiac
19 contractility), the risk of hypoxic episodes probably outweighs this risk in these patients and therefore
20 high FiO₂ should still be given during preoxygenation
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 In other patients, one should ideally aim for a high SpO₂ but at the same time a normal PaO₂ (9,5 –
38 13,5 kPa). As continuous blood gas analysis is normally not feasible or appropriate in the prehospital
39 or ED setting, future studies should investigate if there is a role for non-invasive tools to quantify (and
40 prevent) hyperoxia, for example by estimating the oxygen reserve index (29,30).
41
42
43
44
45
46
47

48 **Limitations**

49
50 Our study has several limitations, inherent to the study design. First, although we observed lower CO
51 and higher SVR values with flush-rate oxygen administration than with 15L/min, we cannot exclude
52 that this is a time-dependent rather than a dose dependent effect, as flush rate oxygen was
53 administered immediately after 5 minutes of 15L/min were administered. Secondly, we did not
54 perform arterial blood gas analysis after pre-oxygenation to establish the presence (and the amount
55
56
57
58
59
60

1
2
3 of) hyperoxia. Nonetheless, the presence of hyperoxemia is highly likely, as SpO₂ increased to 100% in
4 all participating subjects, and previous studies with comparable oxygen administration strategies have
5 demonstrated the presence of both a high expired oxygen fraction (3, 31) and a high PaO₂. In addition,
6
7
8
9
10 14 patients had to be excluded as no reliable ClearSight® signal could be obtained, sometimes for
11 unknown reasons, which could have contributed to selection bias. Also, at least a quarter of the
12 patients used alcohol (n=15) or nicotine (n=17) in the last 24 hours. Since chronic abuse of nicotine
13 and/or alcohol can lead to cardiovascular impairment, for example by decreasing coronary blood flow,
14 this could also be a confounding factor (32,33). In addition, 25% of the patients included used
15 cardiovascular medication that could have interacted with the body's response to a drop in SV and CO
16 from hyperoxia. However, this probably reflects the normal target population in the ED. Finally,
17 generalizability of our results is limited due to the selection of our study population: None of our
18 patients had significant cardiovascular co-morbidity. Therefore no conclusions can be drawn regarding
19 how hyperoxia would affect patients with heart failure, especially when they already have a
20 compromised CO.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Conclusion**

41
42 Exposure of patients to a high FiO₂ for 5-10 minutes results in a significant drop in CO in 1 out of 4
43 patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited
44 amount of time, FiO₂ should be titrated based on deficit and high flow oxygen should not be given as
45 a routine treatment.
46
47
48
49
50
51
52
53

54 **Acknowledgments:** We want to thank dr. Jack J.M. Ligtenberg for his guidance and discussions during
55 this study. We also want to thank all the residents of the Medical Centre Leeuwarden for their help
56 with the inclusion of patients.
57
58
59
60

Declarations

Competing interests: The authors declare that they have no competing interests.

Funding: This work was financially supported by the MCL Research academy (purchase of the finger cuffs). The ClearSight® system was made available at no costs by Edward Lifesciences (reference number NL2018.051). Funding institutions had no role in conception, design, or conduct of the study; collection, management, analysis, interpretation, or presentation of the data; or preparation, review, or approval of the manuscript.

Ethics approval and consent to participate: Regionale toetsingscommissie patiëntgebonden onderzoek (RTPO) Leeuwarden, protocol number nWMO 270. Written consent to participate was obtained.

Consent for publication: not applicable.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author's contributions: All authors fulfilled the ICMJE criteria for authorship. RS and EtA conceived the study. EvI, RS and EtA acquired and interpreted the data. RS and EtA drafted the manuscript. All authors revised the manuscript critically and gave final approval to submission of the manuscript.

References

(1) ACEP Clinical policy for procedural sedation and analgesia in the emergency department. AnnEmergMed 1998;663-77.

- 1
2
3 (2) American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non
4 Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists.
5 Anesthesiology. 2002;96:1004-17/1996;84:458-71.
6
7
- 8 (3) Thomson D, Cowan T, Loten C, Botfield C, Holliday E, Attia J. High-flow oxygen in patients
9 undergoing procedural sedation in the emergency department: A retrospective chart review. Emerg
10 Med Australas 2017 Feb;29(1):33-39.
11
12
- 13 (4) Driver BE, Prekker ME, Kornas RL, Cales EK, Reardon RF. Flush Rate Oxygen for Emergency Airway
14 Preoxygenation. Ann Emerg Med 2017 Jan;69(1):1-6 .
15
16
- 17 (5) Bouroche G, Bourgain J. Preoxygenation and general anesthesia: a review. Minerva Anesthesiol
18 2015; 81(8): 910-20.
19
- 20 (6) Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, et al. Arterial hyperoxia and
21 mortality in critically ill patients: a systematic review and meta-analysis. Crit Care 2014 Dec
22 23;18(6):711-014-0711-x
23
24
- 25 (7) Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of Conservative vs
26 Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-
27 ICU Randomized Clinical Trial. JAMA 2016 Oct 18;316(15):1583-1589.
28
29
- 30 (8) de Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PH, et al. Association
31 between administered oxygen, arterial partial oxygen pressure and mortality in mechanically
32 ventilated intensive care unit patients. Crit Care 2008;12(6):R156.
33
34
- 35 (9) Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, et al. Association between
36 arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA 2010
37 Jun 2;303(21):2165-2171.
38
39
- 40 (10) Eastwood G, Bellomo R, Bailey M, Taori G, Pilcher D, Young P, et al. Arterial oxygen tension and
41 mortality in mechanically ventilated patients. Intensive Care Med 2012 Jan;38(1):91-98.
42
43
- 44 (11) Gao Z, Spilk S, Momen A, et al. Vitamin C prevents hyperoxia-mediated coronary
45 vasoconstriction and impairment of myocardial infarction in healthy subjects. Eur J Appl Physiol
46 2012; 112(2): 483-92.
47
48
- 49 (12) Mak S, Egri Z, Tanna G, et al. Vitamin C prevents hyperoxia-mediated vasoconstriction and
50 impairment of endothelium-dependent vasodilation. Am J Physiol Heart Circ Physiol 2002; 282(6):
51 H2414-21.
52
53
- 54 (13) Haque WA, Boehmer J, Clemson BS, Leuenberger UA, Silber DH, Sinoway LI. Hemodynamic
55 effects of supplemental oxygen administration in congestive heart failure. J Am Coll Cardiol 1996
56 Feb;27(2):353-357.
57
58
59
60

- 1
2
3 (14) Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling
4 pressures in patients with and without congestive heart failure. *Chest* 2001 Aug;120(2):467-473.
5
6 (15) McNulty PH, King N, Scott S, Hartman G, McCann J, Kozak M, et al. Effects of supplemental
7 oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. *Am J*
8 *Physiol Heart Circ Physiol* 2005 Mar;288(3):H1057-62.
9
10 (16) Rousseau A, Bak Z, Janerot-Sjoberg B, Sjoberg F. Acute hyperoxaemia-induced effects on
11 regional blood flow, oxygen consumption and central circulation in man. *Acta Physiol Scand* 2005
12 Mar;183(3):231-240.
13
14 (17) Leitch P, Hudson A, Griggs J, et al. Incidence of hyperoxia in trauma patients receiving pre-
15 hospital emergency anaesthesia: results of a 5-year retrospective analysis. *Scand J Trauma Resusc*
16 *Emerg Med* 2021; 29(1): 134.
17
18 (18) Ameloot K, van de Vijver K, Broch O, et al. Nexfin noninvasive hemodynamic monitoring:
19 validation against continuous pulse contour and intermittent transpulmonary thermodilution
20 derived cardiac output in critically ill patients. *ScientificWorldJournal*. 2013 Nov 11;2013:519080.
21
22 (19) Boisson M, Poignard M, Pontier B, et al. Cardiac output monitoring with thermodilution pulse-
23 contour analysis vs. non-invasive pulse-contour analysis. *Anaesthesia* 2019;74(6):735-740.
24
25 (20) Delaney L, Bellomo R, van Haren F. Responsiveness of non-invasive continuous cardiac output
26 monitoring during the valsalva maneuver. *Clin Nurs Res* 2020; 29(2): 127-132.
27
28 (21) de Wilde R, Schreuder J, van den Berg P, et al. An evaluation of cardiac output by five arterial
29 pulse contour techniques during cardiac surgery. *Anaesthesie* 2007; 62(8): 760-8.
30
31 (22) Hall, J. E. (2011). *Guyton and Hall textbook of medical physiology* (12th ed.). New York: Elsevier
32
33 (23) Stolmeijer R, Bouma HR, Zijlstra JG, et al. A systematic review of the effects of hyperoxia in
34 acutely ill patients: should we aim for less? *Biomed Res Int* 2018;
35 <https://doi.org/10.1155/2018/7841295>.
36
37 (24) Rubanyi G. Vascular effects of oxygen-derived free radicals. *Free Radic Biol Med* 1988;4(2):107-
38 20.
39
40 (25) Smit B, Smulders YM, Eringa EC, et al. Effects of hyperoxia on vascular tone in animal models:
41 systematic review and meta-analysis. *Critical Care* 2018: [https://doi.org/10.1186/s13054-018-2123-](https://doi.org/10.1186/s13054-018-2123-9)
42 9.
43
44 (26) D'Aquila P, Bellizzi D, Passarino G. Mitochondria in health, aging and diseases: the epigenetic
45 perspective. *Biogerontology*. 2015;16(5):569-85.
46
47 (27) Granata S, Dalla Gassa A, Tomei P, et al. Mitochondria: a new therapeutic target in chronic
48 kidney disease. *Nutrition & metabolism*. 2015;12:49.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (28) Wang Y, Hekimi S. Mitochondrial dysfunction and longevity in animals: Untangling the knot.
4 Science. 2015;350(6265):1204-7.

5
6 (29) Scheeren T, Belda F, Perel A. The oxygen reserve index (ORI): a new tool to monitor oxygen
7 therapy. J Clin Monit Comput 2018;32(3):379-389.

8
9 (30) Vos J, Willems H, van Amsterdam K, et al. Oxygen reserve index: validation of a new variable.
10 Anesth Analg 2019;129(2):409-415.

11
12 (31) Driver B, Prekker M, Komar R, et al. Flush rate oxygen for emergency airway preoxygenation.
13 Ann Emerg Med 2017; 69(1): 1-6.

14
15 (32) Kenneth J, Mukamal M. The effects of smoking and drinking on cardiovascular disease and risk
16 factors. Alcohol Res Health 2006; 29(3): 199-202.

17
18 (33) Jalali Z, Khademalhosseini M, Soltani N, et al. Smoking, alcohol and opioids effect on coronary
19 microcirculation: an update overview. BMC Cardiovasc Disord 2021; 21: 185.
20
21
22
23
24
25
26
27
28

29 **Figures:**

30 31 32 **Figure 1. Study Overview**


33
34 *Legend Figure 1: Arrows indicate moments of measurement of haemodynamic parameters.*
35
36
37
38
39

40 **Figure 2. Patient inclusion**


41
42
43
44
45
46
47 **Figure 3. Boxplots of stroke volume (SV) and systemic vascular resistance (SVR) as a function of**
48 oxygen administration in the emergency department (ED), stratified by response in CO (>10%
49 decrease or < 10% decrease).
50
51

52
53 **Legend figure 3:** Represented are median, IQR and ranges (with outliers). Grey boxes represent subjects with a
54 > 10% decrease in CO (n=16). White boxes represent subjects with a <10% decrease in CO during the course of
55 the pre-oxygenation (n=44). Times on the x-axis are baseline, after 5 minutes and after 10.
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only

Figure 2. Patient inclusion

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	4	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7	
Bias	9	Describe any efforts to address potential sources of bias	6-7	
Study size	10	Explain how the study size was arrived at	7	

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	7-8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8-9
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-12

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Haemodynamic effects of a 10-minute treatment with a high inspired oxygen concentration in the Emergency Department: a prospective observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059848.R2
Article Type:	Original research
Date Submitted by the Author:	29-Jun-2022
Complete List of Authors:	Stolmeijer, Renate; University Medical Centre Groningen, Department of Emergency Medicine VAN IEPEREN, Ellen; Medical Centre Leeuwarden, Department of Emergency Medicine LAMEIJER, Heleen; Medical Centre Leeuwarden, Department of Emergency Medicine VAN BEEST, Paul; Medical Centre Leeuwarden, Department of Anaesthesiology ter Maaten, Jan; University Medical Centre Groningen, Emergency Department, Department of internal medicine ter Avest, Ewoud; University Medical Centre Groningen
Primary Subject Heading:	Emergency medicine
Secondary Subject Heading:	Anaesthesia
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Adult intensive & critical care < ANAESTHETICS, INTENSIVE & CRITICAL CARE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Haemodynamic effects of a 10-minute treatment with a high inspired oxygen concentration in the**
4
5 **Emergency Department: a prospective observational study.**
6
7
8
9

10 Renate STOLMEIJER¹, Ellen VAN IEPEREN², Heleen LAMEIJER², Paul VAN BEEST³, Jan C. TER
11
12 MAATEN⁴, Ewoud TER AVEST^{1,5}.
13
14
15

16 ¹ Department of Emergency Medicine, University Medical Centre Groningen, the Netherlands.
17

18 ² Department of Emergency Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
19

20 ³ Department of Anaesthesiology, Medical Centre Leeuwarden, the Netherlands.
21

22 ⁴ Department of Internal Medicine, University Medical Centre Groningen, the Netherlands.
23

24 ⁵ HEMS, Kent, Surrey and Sussex Air Ambulance Trust, Redhill, Surrey, United Kingdom.
25
26
27
28
29

30 **Correspondence to:**

31
32 Renate Stolmeijer, MD: t.m.stolmeijer@umcg.nl
33
34
35
36

37 **Short title:** The effects of short term hyperoxia on cardiac output in the ED.
38
39
40

41 **Word count:** 3949
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Previous studies show that prolonged exposure to a high inspired oxygen concentration (FiO_2) is associated with unfavourable hemodynamic effects. Until now, it is unknown if similar effects also occur after oxygen therapy of limited duration in the emergency department (ED).

Objectives. To investigate the hemodynamic effects of a high FiO_2 administered for a limited duration of time in patients who receive preoxygenation for procedural sedation and analgesia (PSA) in the ED.

Design, settings and participants. In a prospective cohort study, cardiac output (CO), stroke volume (SV) and systemic vascular resistance (SVR) were measured using the ClearSight® non-invasive CO monitoring system in patients who received preoxygenation for PSA in the ED. Measurements were performed at baseline, after 5 minutes of preoxygenation via a non-rebreathing mask at 15/L min and after 5-minutes of flush rate oxygen administration.

Outcomes measures. The primary outcome was defined as the change in CO (L/min) from baseline after subsequent preoxygenation with 15L/min and flush rate.

Results. Sixty patients were included. Mean CO at baseline was 6.5 (6.0-6.9)L/min and decreased to 6.3 (5.8-6.8) L/min after 5 minutes of oxygen administration at a rate of 15L/min, and to 6.2 (5.7-6.70) L/min after another 5 minutes at flush rate ($p=0.037$). Mean SV remained relatively constant during this period, whereas mean SVR increased markedly (from 781 [649-1067], to 1244 [936-1695] to 1337 [988-1738] dyn/sec/cm⁻⁵, $p<0.001$). Sixteen (27%) patients experienced a >10% decrease in CO.

Conclusion. Exposure of patients to a high FiO_2 for 5-10 minutes results in a significant drop in CO in 1 out of 4 patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited amount of time, FiO_2 should be titrated based on deficit whenever this is feasible and high flow oxygen should not be given as a routine treatment.

1
2
3 **Key words:** hyperoxia, inspired oxygen concentration, hyperoxemia, emergency department, oxygen
4
5 therapy, procedural sedation and analgesia.
6
7
8
9

10 **Strengths and limitations of this study:**

- 11 • This prospective study investigates the hemodynamic effects of treatment of patients in the
12 emergency department with a high inspired oxygen concentration for a limited duration of
13 time (10 minutes).
14
- 15 • Non-invasive monitoring of cardiac output, stroke volume and systemic vascular resistance
16 was used before- and during pre-oxygenation to quantify hemodynamic effects.
17
- 18 • Generalizability this study is limited due to relative homogeneity of the subjects included in
19 the study.
20
21
22
23
24
25
26
27
28
29

30 **Background**

31
32 Oxygen is frequently administered in the Emergency Department (ED) and in the prehospital setting
33 by emergency medical services (EMS). It is used both to treat or prevent hypoxia in acutely ill patients
34 and to pre-oxygenate (de-nitrogenate) patients for procedures such as rapid sequence induction (RSI)
35 or procedural sedation and analgesia (PSA), (1-3). Often, oxygen is administered at a flow of 15 L/min
36 or even higher (4) via a non-rebreathing mask (NRBM) in order to increase the end-expiratory oxygen
37 fraction, and to de-nitrogenate the lungs, thereby increasing the safe apnea time for PSA or RSI (5).
38
39
40
41
42
43
44
45
46
47
48

49 Oxygen administration however, may not be without risk. Previous studies show that prolonged
50 exposure to a high inspired oxygen concentration (FiO_2) is associated with higher mortality rates in
51 patients hospitalised with various conditions (6-10). This may be explained by a negative effect on
52 cardiac output (CO), mediated by peripheral and coronary vasoconstriction, resulting from direct
53 effects of oxygen on smooth muscle tone (11,12), and by the formation of reactive oxygen species
54 that contribute to (vascular) oxidative stress (13-16).
55
56
57
58
59
60

1
2
3
4
5
6 As opposed to hospitalised patients, patients in the prehospital setting and in the ED normally receive
7 high-flow oxygen only for a limited amount of time. Previous studies show nonetheless that this results
8 in significant hyperoxemia in many patients (17). The clinical relevance of this however is largely
9 unknown, as until now the hemodynamic effects of exposure of patients in the ED to a high FiO_2 for
10 only a limited duration of time have never been reported.
11
12
13
14
15
16
17
18
19
20

21 Therefore, in the present study, we aim to investigate the hemodynamic effects of a high FiO_2
22 administered for only a limited duration of time in patients who receive preoxygenation for PSA in the
23 ED.
24
25
26
27
28
29

30 **Methods**

31 Study Setting and Design

32 A single centre prospective study was performed in a cohort of patients undergoing pre-oxygenation
33 for PSA in the ED of the Medical Centre Leeuwarden (a teaching hospital in the Netherlands with an
34 27.000 ED visits yearly) between May 2018 to June 2019 (ClinicalTrials.gov (NCT03930979). Ethical
35 approval was sought and obtained from the ethical committee of the RTPO Leeuwarden (protocol
36 number nWMO 270).
37
38
39
40
41
42
43
44
45
46
47

48 Patient and public involvement

49 No patients were involved in the design, recruitment or conduct of this study.
50
51
52
53
54

55 Study population

56 Patients were eligible for inclusion in the study if they were older than 18 years and were about to
57 receive PSA to facilitate a procedure in ED. Patients were excluded if PSA was needed immediately
58
59
60

1
2
3 according to the treating physician (no time to obtain informed consent and/or to perform necessary
4 calibration of the system used to measure CO), if they were pregnant, if they presented with
5 significant hypoxia (defined as an oxygen saturation <90% or a pO₂< 8.0 kPa), if they received oxygen
6 suppletion pre-inclusion, if they had chronic obstructive pulmonary disease (COPD) GOLD I or II with
7 hypercapnia (pCO₂ >6.4 kPa) or COPD GOLD III or IV, if they used bleomycine, if they presented with
8 a cardiogenic shock (SBP<90 mmHg) or if they needed PSA for electrocardioversion- or pacing (for
9 reasons of difficulty obtaining a reliable signal to measure CO). Patients could only be included once.
10
11
12
13
14
15
16
17
18
19
20
21

22 Study protocol

23
24 After informed consent was obtained from eligible patients, demographics, medical history and
25 medication use, ECG at presentation and vital signs were obtained. Subsequently, the Clearsight® non-
26 invasive cardiac output measurement system was attached to the patient and calibrated for
27 continuous monitoring of blood pressure, CO, SV and SVR. Baseline values for these parameters were
28 established as an average of three repeated measurements. Thereafter, oxygen was administered via
29 a NRBM at a rate of 15L/min from a powered wall source, and measurements (CO, CI, SV, and SVR)
30 were repeated after 5 minutes. Thereafter, the rate of oxygen administration was increased to flush
31 rate (30L/min) and after 5 minutes measurements were repeated. No other interventions than oxygen
32 administration were performed during this period, and no medication or intravenous fluids were
33 administered. Thereafter, care as usual was provided for the conduct of PSA. (figure 1)
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Data collection

50
51 The following parameters were collected on a dedicated Case Report Form (CRF) for all included
52 patients: patient demographics including (cardiac) medical history and alcohol- nicotine- and
53 medication use, ECG abnormalities at presentation, ASA classification and indication for PSA, and vital
54 parameters (heart rate (HR), non-invasively measured systolic blood pressure (SBP), oxygen saturation
55 (SpO₂), CO, SV and SVR).
56
57
58
59
60

Non-invasive cardiac output measurements

CO was measured non-invasively using The ClearSight® system (Edwards Lifesciences). The methodology of the ClearSight® is based on Nexfin technology. This consists of pulsatile unloading of the finger arterial walls using an inflatable finger cuff with a built-in photoelectric plethysmograph that uses pressure to maintain a constant blood volume in the finger. ClearSight® calculates beat-to-beat SV by dividing the area under the SBP curve (measured at 200 Hz) by the aortic input impedance (Zin). The value of Zin is determined from a three-element Windkessel model in which the nonlinear effect of MAP and the influence of the patient's age, height, weight, and gender on aortic mechanical properties are incorporated. Because the waveform at the finger shows a more undulatory appearance than the radial pressure waveform, the system transforms the finger waveform into a brachial waveform with a specific filter. ClearSight® uses the integrated area under the pulsatile systolic waveform from the brachial pressure wave as an input to the model, which directly yields SV and produces CO by multiplying beat-to-beat SV by instantaneous heart rate. The Nexfin technology used in the ClearSight® is validated in multiple studies (18,19). Measurements can reliably be performed in awake patients or during cardiac arrhythmias (20-22), but hypoperfusion of the finger (due to vasoconstriction) from shock, hypothermia, or the use of vasopressors may negatively impact signal reliability (18,19). All investigators received training given by a trainer of the manufacturer of ClearSight® in how to operate the device before they were able to include patients for this study.

Outcomes

The primary outcome was defined as the absolute change in CO from baseline after respectively 5 minutes 15L O₂/min and 5 minutes flush rate oxygenation via a NRBM.

Secondary outcomes were defined as:

- The absolute change in HR, SBP, SV and SVR from baseline after respectively 15L O₂/min and

1
2
3 flush rate oxygenation via NRBM.
4

- 5 - The number of subjects demonstrating a >10% change in CO* in response to oxygen
6
7 administration (both 15L/min and Flush rate).
8
9

10
11
12 * a 10% change in CO was deemed clinically relevant as this corresponds to the effect of a Valsalva
13 manoeuvre (23) and has been shown to be a detectable change using a (non-invasive) method based
14 on pulse contour analysis (24).
15
16
17
18
19
20
21
22

23 Sample size

24 Based on previous literature (25) it was estimated that with a mean (SD) CO of 6.0 (0.8) L/min, 54
25 patients are necessary to allow the detection of a 10% decrease in CO as a result of procedural
26 sedation with a power of 90% and a type I error rate of 5%. To allow for an attrition rate of 10 % we
27 aimed to include 60 patients.
28
29
30
31
32
33
34
35
36
37

38 Statistical analysis

39 Continues variables are represented as mean (95% CI) or median (IQR) where appropriate. Repeated
40 measures ANOVA with Greenhouse Geiser correction and post-hoc testing (Tukey Kramer) was used
41 to analyze the difference in hemodynamic measurements at baseline and after preoxygenation with
42 NRBM 15L/min and flush rate oxygen. Comparisons between patients demonstrating a > 10% decrease
43 in CO and those who did not were made using Student's t-test, Mann-Whitney U test, or Fisher's exact
44 test where appropriate. Mixed ANOVA was used to calculate oxygen dose-to-group interactions for
45 these groups. Missing data was reported in the results section according to the STROBE guideline. A
46 p -value <0.05 was considered statistically significant. All statistical analysis were done with SPSS 23.0
47 for Apple statistical package (SPSS Inc, Chicago, Illinois, USA) and Vassarstats statistical software (Vassar
48 college, Poughkeepsie, New York, USA).
49
50
51
52
53
54
55
56
57
58
59
60

Results

Characteristics of study population

During the study period, a total of 91 patients were screened for eligibility. Thirty-one patients were excluded after screening due to various reasons (figure 2). Fourteen patients were excluded as no reliable signal for cardiac output monitoring could be obtained. In 6/14 patients this was due to identifiable patient factors (cold hands, tremor), whereas in the remaining 8 patients the system software failed.

Baseline characteristics of the study population are shown in table 1. Median (range) age of the included subjects was 62 (18-92) years, with an equal gender distribution. A total of 16 patients (26,7%) used one or more cardiovascular drugs on a daily basis. There were no patients with pre-existent heart failure or a pacemaker in situ. Other patient characteristics, and vital signs at presentation are represented in table 1. None of the patients received intravenous fluids before arrival in hospital. Sometimes they did receive analgesics administered by EMS; fentanyl (n=25 (41,7%)), ketamine (n=12 (20%)) or other opioids (n=4 (6,7%)).

Table 1. Baseline characteristics of patients pre-oxygenated with a high (FiO₂) for PSA in the ED (n=60).

Age in years, median (range)	62 (18-92)
Gender, n (%)	
Female	30 (50)
Male	30 (50)
Cardiovascular Medication use, n (%)	

Beta blocker	10 (16,7)
ACE inhibitor or ATII receptor antagonist	12 (20)
Spironolactone	1 (1,7)
Calcium channel blockers	0 (0)
Known heart failure, n (%)	0 (0)
Pacemaker, n (%)	0 (0)
Abnormality on ECG, n (%)*	3 (5)
ASA classification, n (%)	
I	21 (35)
II	26 (43,3)
III	13 (21,7)
IV	0 (0)
Use of alcohol < 24 hours, n (%)	17 (29,8)
Use of nicotine < 24 hours, n (%)	15 (26,3)
Indication PSA, n (%)	
Reduction dislocation	34 (56,7)
Reduction fracture	8 (13,3)
Incision and drainage abscess	17 (28,3)
Chest tube placement**	1 (1,7)

Legend table 1. ACE, Angiotensin converting enzyme; ATII, angiotensin type 2; ECG, electrocardiogram; ASA, American Society of Anaesthesiologists; PSA, procedural sedation and analgesia. * atrial fibrillation. ** Indication for the chest tube was a large pneumothorax, without signs of hypoxia, or respiratory- or hemodynamic compromise.

Main results

Oxygen administration at a rate of 15L/min during pre-oxygenation resulted in an increase in median oxygen saturation (from 97% to 100%), $p < 0.0001$. Mean (95% CI) CO at baseline was 6.5 (6.0-6.9) L/min, and decreased to 6.3 (5.8-6.8) L/min after 5 minutes of oxygen administration by NRB at a rate

of 15L/min, and to 6.2 (5.7-6.7) L/min after a further 5 minutes of flush rate oxygen suppletion ($p=0.037$). Mean SV remained relatively constant, whereas mean SVR increased markedly (table 2).

Table 2. Non-invasively measured (haemodynamic) variables before- and after pre-oxygenation with a high (FiO_2) for PSA in the ED (n=60).

	Baseline N = 60	After 5 minutes NRBM 15L/min N = 60	After 5 minutes flush rate oxygen N = 59	p
SpO ₂ (%)	97 (97 – 98)	100 (100 – 100)*	100 (100 – 100)*	<0.001
CO (L/min)	6.5 (6.0 - 6.9)	6.3 (5.8 - 6.8)	6.2 (5.7 - 6.7)*	0.037
SV (ml)	84 (77 – 89)	83 (75 – 89)	83 (75 – 90)	0.69
SBP (mmHg)	133 (123-151)	138 (125 – 164)*	144 (132 – 162)* ≠	<0.001
HR (bpm)	78 (74 – 81)	76 (72 – 80)	76 (72 – 80)	0.064
SVR (dyn/sec/cm ⁻⁵)	781 (649-1067)	1244 (936 – 1695)*	1337 (988 – 1738)* ≠	<0.001

Legend table 2: Values are mean [95%CI] (CO, SV and HR) or median [IQR] (SpO₂, SBP, and SVR). Represented are P values for repeated measures ANOVA omnibus test. * denotes $p<0.05$ in post-hoc testing compared to baseline; ≠ denotes $p<0.05$ compared to 15L/min. CO, cardiac output;; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SpO₂, oxygen saturation; SVR, systemic vascular resistance.

A considerable proportion of the subjects (n=16, 27%) demonstrated a >10% decrease in CO in response to preoxygenation: In about a third of the subjects (n= 5) this was already apparent after the first 5 minutes of preoxygenation with a NRBM at a rate of 15L/min. Baseline patient characteristics were not significantly related to the occurrence of a > 10% decrease in CO (table 3).

Table 3. Baseline patient characteristics stratified by the effect of pre-oxygenation with a high (FiO₂) for PSA in the ED (n=60).

	Patients with a >10 % decrease in CO (n = 16)	Other patients (n = 44)	p
Demographics and history			
Male (n)	5 (31%)	25 (57%)	0.14
Age (years)	67.5 (45.3 – 77.0)	60 (36.3 – 74.5)	0.45
ASA III classification (n)	2 (13%)	11 (25%)	0.48
Use of alcohol <24 hours (n)	5 (31%)	12 (27%)	0.76
Use of nicotine <24 hours (n)	2 (13%)	13 (30%)	0.31
Any cardiovascular medication use (n)	4 (25%)	12 (27%)	1.00
Physical exam			
SpO ₂ (%)	97 (96-99)	97 (97-98)	0.98
HR (bpm)	77 (70-82)	78 (74-82)	0.72
SBP	138 (124-160)	133 (123-149)	0.63
CO (L/min)	6.6 (5.6 – 7.5)	6.4 (5.9 – 7.0)	0.73
SV (ml)	86 (73 – 99)	83 (76 – 90)	0.59
SVR (dyn/sec/cm ⁻⁵)	735 (637 – 1142)	846 (649 – 1042)	0.82

Legend table 3: Values are mean [95% CI] (CO, SV and HR) or median [IQR] (SpO₂, SBP, and SVR). CO, cardiac output; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SpO₂, oxygen saturation; SVR, systemic vascular resistance.

Patients who demonstrated a >10% decrease in CO had a significantly greater increase in SVR (from 735 dyn/sec/cm⁻⁵ at baseline to 1248 dyn/sec/cm⁻⁵ after 15L/min to 1482 dyn/sec/cm⁻⁵ after flush rate oxygen suppletion) compared to other patients (846, 1244 and 1304 dyn/sec/cm⁻⁵ respectively), p=0.025), figure 3 and table 4. Likewise, they demonstrated a significant decrease in SV (from 86 ml to 80 ml and 76 ml respectively), whereas SV did not decrease in patient who did not demonstrate a clinically relevant decrease in CO (83, 84 and 86 ml respectively, p<0.001).

Table 4. Haemodynamic parameters as a function of oxygen administration, stratified by the response in CO (>10% decrease or < 10% decrease).

	>10% decrease in CO N = 16	Other patients N = 44	p
CO (L/min)			<0.001
Baseline	6.6 (5.6 – 7.5)	6.4 (5.9 – 7.0)	
Oxygen 15L/min	6.2 (5.2 – 7.2)	6.3 (5.7 – 6.9)	
Oxygen Flush rate	5.4 (4.6 – 6.2)	6.5 (5.9 – 7.1)	
SV (ml)			<0.001
Baseline	86 (73 – 99.)	83 (76 – 90)	
Oxygen 15L/min	80 (66 – 95)	84 (76 – 92)	
Oxygen Flush rate	76 (61 – 92)	86 (77 – 94)	
SVR dyn/sec/cm⁵)			0.025
Baseline	735 (637 – 1142)	846 (649 – 1042)	
Oxygen 15L/min	1248 (950 – 1954)	1244 (910 – 1658)	
Oxygen Flush rate	1482 (1129 – 2214)	1304 (982 – 1672)	
HR (bpm)			0.85
Baseline	77 (70– 82)	78 (74 – 82)	
Oxygen 15L/min	75 (68 – 81)	77 (72 – 81)	
Oxygen Flush rate	75 (68 – 81)	77 (72 – 82)	
SBP (mmHg)			0.26
Baseline	138 (124 – 160)	133 (123 – 150)	
Oxygen 15L/min	147 (117 – 164)	137 (129 – 164)	
Oxygen Flush rate	148 (127 – 165)	144 (132 – 158)	

Legend table 4. Values are depicted as mean [95%CI] (CO, SV, HR) or median [IQR] (SBP, SVR). Represented P value are for the oxygen dose-to-group interaction in mixed ANOVA. T=5; value after 5 minutes of oxygen administration by NRBM at a rate of 15L/min; T=10; value after an additional 5 minutes of oxygen administration by NRBM at flush rate. CO, cardiac output; SV, stroke volume; HR, heart rate; SBP, systolic blood pressure; SVR, systemic vascular resistance.

Discussion

In this study, we found that a short 10-minute exposure to a high FiO_2 is associated with a significant drop in mean CO. This stresses the importance of titrated oxygen administration in the ED and in prehospital care whenever this is feasible: Clinicians should carefully balance the risk of hyperoxia against the risk of hypoxia when oxygen is administered, especially in patients with already compromised circulation.

The observed drop in mean CO in this study is in line with previous literature which shows that prolonged exposure to a high FiO_2 has a negative effect on CO (13-16), and (ultimately) on morbidity and mortality (26). The proposed pathophysiological mechanism mediating the relation between hyperoxia and CO is coronary vasoconstriction (13-16), resulting in a decrease in SV. The latter is in line with our finding that SV decreases with >10% in subjects who demonstrated a >10% decrease in their CO, whereas HR remained unchanged. In these patients we also observed a marked increase in SVR (afterload), which may have contributed to the reduction in CO. Although this may be the result of an increased sympathetic tone due to pain and/or stress, we did not observe a concomitant increase in HR. Alternatively, free oxygen radicals have been shown to modulate the tone of vascular smooth muscle both directly and indirectly by affecting the production- or biological activity of vasoactive mediators (27,28). Furthermore, free radicals have the potential to damage (mitochondrial) DNA, lipids and proteins, and may cause irreversible damage (26,29-31). However, we can only speculate about the exact aetiology and the relative contribution of the above mentioned processes, as we did not measure free oxygen radicals and/or oxidative stress in our study.

One in four patients demonstrated a >10% drop in CO. Changes of this magnitude are likely clinically relevant in patient who already have a reduced CO, as previous studies have demonstrated that even in healthy volunteers, a sudden 10% drop in CO (comparable to the effect of a Valsalva manoeuvre) already causes symptoms, whereas a 20% decrease can result in syncope (32,33). Besides, any drop in

1
2
3 CO may be undesirable in critically ill patients who are also more prone to develop dysrhythmia's such
4 as atrial fibrillation, further compromising CO (33). It is worth mentioning however, that not only the
5 magnitude of the drop in CO, but also the duration are relevant for the ultimate effect. As medication
6 for PSA was administered per protocol after the second period of pre-oxygenation, we could not
7 monitor (speed of) recovery of CO in our current study, and therefore future studies should focus on
8 reversibility of the observed changes.
9

10
11
12
13
14
15
16
17
18
19 As 1 in 4 patients demonstrates a >10% drop in CO, it seems reasonable to titrate oxygen
20 administration on SpO₂ in patients, especially in patients with an already compromised circulation,
21 even when oxygen is only administered for a short duration of time, as in the prehospital setting or in
22 ED. This can be achieved relatively easy when oxygen is administered for the purpose of treating or
23 preventing hypoxia. But it is more difficult to achieve when oxygen is administered for the purpose of
24 denitrogenation preceding PSA or RSI and thereby increasing save apnoeic time. In those instances,
25 the risk of short duration hyperoxia should be balanced against the risk of the occurrence of hypoxic
26 episodes when pre-oxygenation with a high FiO₂ is not provided. Although negative effects on CO are
27 undesirable in patients undergoing PSA or RSI (who receive drugs affecting vascular tone and cardiac
28 contractility), the risk of hypoxic episodes probably outweighs this risk in these patients and therefore
29 high FiO₂ should still be given during preoxygenation. Early use of vasopressors to maintain perfusion
30 pressures in the presence of a reduced CO can be considered under these circumstances.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 In other patients, one should ideally aim for a high SpO₂ but at the same time a normal PaO₂ (9,5 –
49 13,5 kPa). As continuous blood gas analysis is normally not feasible or appropriate in the prehospital
50 or ED setting, future studies should investigate if there is a role for non-invasive tools to quantify (and
51 prevent) hyperoxia, for example by estimating the oxygen reserve index (34,35). In the meantime,
52 implementation of checklists, wherein the oxygen requirement and administration are discussed at
53
54
55
56
57
58
59
60

1
2
3 handover from EMS in ED may increase awareness of the risks associated with hyperoxia and prevent
4 administration of oxygen with a higher than necessary FiO_2 .
5
6
7
8
9

10 **Limitations**

11
12 Our study has several limitations, inherent to the study design. First, although we observed lower CO
13 and higher SVR values with flush-rate oxygen administration than with 15L/min, we cannot exclude
14 that this is a time-dependent rather than a dose dependent effect, as flush rate oxygen was
15 administered immediately after 5 minutes of 15L/min were administered. Secondly, we did not
16 perform arterial blood gas analysis after pre-oxygenation to establish the presence (and the amount
17 of) hyperoxia. Nonetheless, the presence of hyperoxemia is highly likely, as SpO_2 increased to 100% in
18 all participating subjects, and previous studies with comparable oxygen administration strategies have
19 demonstrated the presence of both a high expired oxygen fraction (3, 36) and a high PaO_2 . In addition,
20 14 patients had to be excluded as no reliable ClearSight® signal could be obtained, sometimes for
21 unknown reasons, which could have contributed to selection bias. Also, at least a quarter of the
22 patients used alcohol (n=15) or nicotine (n=17) in the last 24 hours. Since chronic abuse of nicotine
23 and/or alcohol can lead to cardiovascular impairment, for example by decreasing coronary blood flow,
24 this could also be a confounding factor (37,38). In addition, 25% of the patients included used
25 cardiovascular medication that could have interacted with the body's response to a drop in SV and CO
26 from hyperoxia. However, this probably reflects the normal target population in the ED. Finally,
27 generalizability of our results is limited due to the selection of our study population: None of our
28 patients had significant cardiovascular co-morbidity. Therefore no conclusions can be drawn regarding
29 how hyperoxia would affect patients with heart failure, especially when they already have a
30 compromised CO.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

Exposure of patients to a high FiO_2 for 5-10 minutes results in a significant drop in CO in 1 out of 4 patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited amount of time, FiO_2 should be titrated based on deficit and high flow oxygen should not be given as a routine treatment.

Acknowledgments: We want to thank dr. Jack J.M. Ligtenberg for his guidance and discussions during this study. We also want to thank all the residents of the Medical Centre Leeuwarden for their help with the inclusion of patients.

Declarations

Competing interests: The authors declare that they have no competing interests.

Funding: This work was financially supported by the MCL Research academy (purchase of the finger cuffs). The ClearSight® system was made available at no costs by Edward Lifesciences (reference number NL2018.051). Funding institutions had no role in conception, design, or conduct of the study; collection, management, analysis, interpretation, or presentation of the data; or preparation, review, or approval of the manuscript.

Ethics approval and consent to participate: Regionale toetsingscommissie patiëntgebonden onderzoek (RTPO) Leeuwarden, protocol number nWMO 270. Written consent to participate was obtained.

Consent for publication: not applicable.

1
2
3 Availability of data and materials: The datasets used and/or analyzed during the current study are
4 available from the corresponding author on reasonable request.
5
6
7
8
9

10 Author's contributions: All authors fulfilled the ICMJE criteria for authorship. RS and EtA conceived the
11 study. EvI, RS and EtA acquired and interpreted the data. RS and EtA drafted the manuscript. HL, PvB
12 and JtM revised the manuscript critically and gave final approval to submission of the manuscript.
13
14
15
16
17
18
19
20

21 **References**

- 22 (1) ACEP Clinical policy for procedural sedation and analgesia in the emergency department.
23 AnnEmergMed 1998;663-77.
24
25 (2) American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non
26 Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists.
27 Anesthesiology. 2002;96:1004-17/1996;84:458-71.
28
29 (3) Thomson D, Cowan T, Loten C, Botfield C, Holliday E, Attia J. High-flow oxygen in patients
30 undergoing procedural sedation in the emergency department: A retrospective chart review. Emerg
31 Med Australas 2017 Feb;29(1):33-39.
32
33 (4) Driver BE, Prekker ME, Kornas RL, Cales EK, Reardon RF. Flush Rate Oxygen for Emergency Airway
34 Preoxygenation. Ann Emerg Med 2017 Jan;69(1):1-6 .
35
36 (5) Bouroche G, Bourgain J. Preoxygenation and general anesthesia: a review. Minerva Anesthesiol
37 2015; 81(8): 910-20.
38
39 (6) Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, et al. Arterial hyperoxia and
40 mortality in critically ill patients: a systematic review and meta-analysis. Crit Care 2014 Dec
41 23;18(6):711-014-0711-x
42
43 (7) Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of Conservative vs
44 Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-
45 ICU Randomized Clinical Trial. JAMA 2016 Oct 18;316(15):1583-1589.
46
47 (8) de Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PH, et al. Association
48 between administered oxygen, arterial partial oxygen pressure and mortality in mechanically
49 ventilated intensive care unit patients. Crit Care 2008;12(6):R156.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (9) Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, et al. Association between
4 arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA* 2010
5 Jun 2;303(21):2165-2171.
6
7
8 (10) Eastwood G, Bellomo R, Bailey M, Taori G, Pilcher D, Young P, et al. Arterial oxygen tension and
9 mortality in mechanically ventilated patients. *Intensive Care Med* 2012 Jan;38(1):91-98.
10
11 (11) Gao Z, Spilk S, Momen A, et al. Vitamin C prevents hyperoxia-mediated coronary
12 vasoconstriction and impairment of myocardial infarction in healthy subjects. *Eur J Appl Physiol*
13 2012; 112(2): 483-92.
14
15 (12) Mak S, Egri Z, Tanna G, et al. Vitamin C prevents hyperoxia-mediated vasoconstriction and
16 impairment of endothelium-dependent vasodilation. *Am J Physiol Heart Circ Physiol* 2002; 282(6):
17 H2414-21.
18
19 (13) Haque WA, Boehmer J, Clemson BS, Leuenberger UA, Silber DH, Sinoway LI. Hemodynamic
20 effects of supplemental oxygen administration in congestive heart failure. *J Am Coll Cardiol* 1996
21 Feb;27(2):353-357.
22
23 (14) Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling
24 pressures in patients with and without congestive heart failure. *Chest* 2001 Aug;120(2):467-473.
25
26 (15) McNulty PH, King N, Scott S, Hartman G, McCann J, Kozak M, et al. Effects of supplemental
27 oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. *Am J*
28 *Physiol Heart Circ Physiol* 2005 Mar;288(3):H1057-62.
29
30 (16) Rousseau A, Bak Z, Janerot-Sjoberg B, Sjoberg F. Acute hyperoxaemia-induced effects on
31 regional blood flow, oxygen consumption and central circulation in man. *Acta Physiol Scand* 2005
32 Mar;183(3):231-240.
33
34 (17) Leitch P, Hudson A, Griggs J, et al. Incidence of hyperoxia in trauma patients receiving pre-
35 hospital emergency anaesthesia: results of a 5-year retrospective analysis. *Scand J Trauma Resusc*
36 *Emerg Med* 2021; 29(1): 134.
37
38 (18) Ameloot K, van de Vijver K, Broch O, et al. Nexfin noninvasive hemodynamic monitoring:
39 validation against continuous pulse contour and intermittent transpulmonary thermodilution
40 derived cardiac output in critically ill patients. *ScientificWorldJournal*. 2013 Nov 11;2013:519080.
41
42 (19) Boisson M, Poignard M, Pontier B, et al. Cardiac output monitoring with thermodilution pulse-
43 contour analysis vs. non-invasive pulse-contour analysis. *Anaesthesia* 2019;74(6):735-740.
44
45 (20) Bogert L, Wesseling K, Schraa O, et al. Pulse countour cardiac output derived from non-invasive
46 arterial pressure in cardiovascular disease. *Aneesthesia* 2010; 65(11): 1119-25.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (21) Berkelmans G, Kuipers S, Westerhof B, et al. Comparing volume-clamp method and intra-arterial
4 blood pressure measurements in patients with arterial fibrillation admitted to the intensive or
5 medium care unit. *J Clin Monit Comput* 2018; 32(3): 439-446.
6
7
8 (22) Maggi R, Viscardi V, Furukawa T, et al. Non-invasive continuous blood pressure monitoring of
9 tachycardic episodes during interventional electrophysiology. *Europace* 2010; 12(11): 1616-22.
10
11 (23) Delaney L, Bellomo R, van Haren F. Responsiveness of non-invasive continuous cardiac output
12 monitoring during the valsalva maneuver. *Clin Nurs Res* 2020; 29(2): 127-132.
13
14 (24) de Wilde R, Schreuder J, van den Berg P, et al. An evaluation of cardiac output by five arterial
15 pulse contour techniques during cardiac surgery. *Anaesthesie* 2007; 62(8): 760-8.
16
17 (25) Hall, J. E. (2011). *Guyton and Hall textbook of medical physiology* (12th ed.). New York: Elsevier
18
19 (26) Stolmeijer R, Bouma HR, Zijlstra JG, et al. A systematic review of the effects of hyperoxia in
20 acutely ill patients: should we aim for less? *Biomed Res Int* 2018;
21
22 <https://doi.org/10.1155/2018/7841295>.
23
24 (27) Rubanyi G. Vascular effects of oxygen-derived free radicals. *Free Radic Biol Med* 1988;4(2):107-
25
26 20.
27
28 (28) Smit B, Smulders YM, Eringa EC, et al. Effects of hyperoxia on vascular tone in animal models:
29 systematic review and meta-analysis. *Critical Care* 2018: [https://doi.org/10.1186/s13054-018-2123-](https://doi.org/10.1186/s13054-018-2123-9)
30
31 9.
32
33 (29) D'Aquila P, Bellizzi D, Passarino G. Mitochondria in health, aging and diseases: the epigenetic
34 perspective. *Biogerontology*. 2015;16(5):569-85.
35
36 (30) Granata S, Dalla Gassa A, Tomei P, et al. Mitochondria: a new therapeutic target in chronic
37 kidney disease. *Nutrition & metabolism*. 2015;12:49.
38
39 (31) Wang Y, Hekimi S. Mitochondrial dysfunction and longevity in animals: Untangling the knot.
40 *Science*. 2015;350(6265):1204-7.
41
42 (32) Fu Q, Verheyden B, Wieling W, et al. Cardiac output and sympathetic vasoconstrictor responses
43 during upright tilt to presyncope in healthy humans. *J Physiol* 2012; 590(Pt8): 1839-1848.
44
45 (33) Vincent J. Understanding cardiac output. *Crit Care* 2008; 12(4): 174.
46
47 (34) Scheeren T, Belda F, Perel A. The oxygen reserve index (ORI): a new tool to monitor oxygen
48 therapy. *J Clin Monit Comput* 2018;32(3):379-389.
49
50 (35) Vos J, Willems H, van Amsterdam K, et al. Oxygen reserve index: validation of a new variable.
51 *Anesth Analg* 2019;129(2):409-415.
52
53 (36) Driver B, Prekker M, Komars R, et al. Flush rate oxygen for emergency airway preoxygenation.
54
55 *Ann Emerg Med* 2017; 69(1): 1-6.
56
57
58
59
60

1
2
3 (37) Kenneth J, Mukamal M. The effects of smoking and drinking on cardiovascular disease and risk
4 factors. *Alcohol Res Health* 2006; 29(3): 199-202.

5
6 (38) Jalali Z, Khademalhosseini M, Soltani N, et al. Smoking, alcohol and opioids effect on coronary
7 microcirculation: an update overview. *BMC Cardiovasc Disord* 2021; 21: 185.
8
9

10
11
12
13
14
15 **Figures:**
16


17
18
19 **Figure 1. Study Overview**
20

21 *Legend Figure 1: Arrows indicate moments of measurement of haemodynamic parameters.*
22
23

24
25
26
27 **Figure 2. Patient inclusion**
28
29
30


31
32
33 **Figure 3. Boxplots of stroke volume (SV) and systemic vascular resistance (SVR) as a function of**
34 oxygen administration in the emergency department (ED), stratified by response in CO (>10%
35 decrease or < 10% decrease).
36
37


38
39 *Legend figure 3: Represented are median, IQR and ranges (with outliers). Grey boxes represent subjects with a*
40 *> 10% decrease in CO (n=16). White boxes represent subjects with a <10% decrease in CO during the course of*
41 *the pre-oxygenation (n=44). Times on the x-axis are baseline, after 5 minutes and after 10.*
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Patient inclusion



For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	4	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7	
Bias	9	Describe any efforts to address potential sources of bias	6-7	
Study size	10	Explain how the study size was arrived at	7	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	7-8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8-9
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-12

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.